Progression of white matter hyperintensities is related to blood pressure increases and global cognitive decline – a registered report

Frauke Beyer1,2

Laurenz Lammer2

Markus Loeffler4,5

Steffi Riedel-Heller5,6

Stéphanie Debette1

Arno Villringer2,7

A. Veronica Witte2,3,7

1 Bordeaux Population Health Research Center, University of Bordeaux, Inserm, UMR 1219, Bordeaux, France Department of Neurology  
2 Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig   
3 CRC 1052 “Obesity Mechanisms”, Subproject A1, University of Leipzig   
4 Institute for Medical Informatics, Statistics and Epidemiology; University of Leipzig   
5 Leipzig Research Centre for Civilisation Diseases (LIFE), Leipzig   
6 Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig , Leipzig   
7 Day Clinic for Cognitive Neurology, University Hospital Leipzig, University of Leipzig

# Abstract

## Introduction

Cerebral small vessel disease (cSVD) is a major brain pathology contributing to cognitive decline and dementia. Vascular risk factors have been associated with imaging markers of cSVD such as white matter hyperintensities (WMH), yet longitudinal studies have not comprehensively assessed these effects for abdominal obesity or reported sex/gender-specific effects.

## Methods

In this pre-registered analysis of a longitudinal population-based neuroimaging cohort, we investigated the association of baseline and change in diastolic blood pressure (DBP) and waist-to-hip ratio with WMH progression and the relationship of WMH progression and executive and global cognitive function in linear mixed models. We conducted gender interaction and stratified analyses.

## Results

We included data from 596 individuals (44.1 % females, mean age = 63.2 years) with two MRI scans over approximately 6 years. We did not find a significant association of baseline DBP with WMH progression. WMH progression significantly predicted global cognitive decline but not decline in executive function. In exploratory analyses, increases in DBP as well as baseline and increase in systolic blood pressure were associated with WMH progression, confined to frontal periventricular regions. There were no gender-specific associations of WMH progression with risk factors or cognitive outcomes.

## Conclusion

BP control is recommended to limit WMH progression and negative effects on global cognitive function in the middle-aged to older population for men and women.

# Introduction

Staying cognitively healthy is of paramount importance when we age and dementia is among the most feared diseases in our society (Hajek and König ([2020](#ref-hajekFearDementiaGeneral2020))). Cerebral small vessel disease (cSVD) has increasingly been recognized as a major underlying pathology of cognitive decline and dementia (Bos et al. ([2018](#ref-bos18))). CSVD describes pathologies of the brain’s small arterioles, capillaries and venules which manifest on magnetic resonance imaging (MRI) as focal lesions (white matter hyperintensities[[1]](#footnote-1) (WMH), lacunes, microbleeds, dilated perivascular spaces) and in globally reduced white matter coherence and gray matter atrophy (Wardlaw, Smith, and Dichgans ([2019](#ref-wardlaw19))).   
Most commonly, WMH volume and location are used as a proxy for cSVD due to relatively easy automatic quantification on brain images. Several studies have shown that the presence and extent of cSVD neuroimaging markers are predictive of stroke, future cognitive decline and dementia (Debette et al. ([2019a](#ref-debette19))). While WMH are present in a large proportion of older adults, their occurrence is not random, but their location and extent strongly depend on the presence of vascular risk factors (Jorgensen et al. ([2018](#X839a91eaa77d147468bf0bce3c0d9f17114c68c))). It is well known that elevated blood pressure and hypertension are associated with the appearance and progression of WMH in mid and late life (Dufouil et al. ([2001](#ref-dufouilLongitudinalStudyBlood2001)); Jansen et al. ([2022](#ref-jansen22)), Scharf et al. ([2019](#X003ff1da26a04bcfbabaa823ebecda1d16bd31e)), Vermeer, Longstreth, and Koudstaal ([2007](#ref-vermeer07)); Williamson et al. ([2018](#X75eb2c73042aadb3b39c39432a74ed019d8fd65))) but see (Dickie et al. ([2016](#ref-dickieProgressionWhiteMatter2016)), P. Sachdev et al. ([2007](#ref-sachdevProgressionWhiteMatter2007))). While both systolic and diastolic blood pressure (DBP) are important predictors, effects seem to be more pronounced for DBP (D. Zhang et al. ([2020](#ref-zhangAgeDiastolicBlood2020))). Randomized controlled trials have provided evidence that intensive blood pressure control can reduce the progression of WMH in hypertensive and diabetic patients(de Havenon et al. ([2019](#ref-dehavenonBloodPressureGlycemic2019)); Nasrallah et al. ([2019](#ref-nasrallahAssociationIntensiveVs2019)); H. Zhang et al. ([2019](#ref-zhangEffectsSartansLowdose2019))), yet no consensus on how to specifically target cSVD and related cognitive decline has been reached (Wardlaw, Smith, and Dichgans ([2019](#ref-wardlaw19))).   
More recently, abdominal obesity has emerged as a risk factor for cSVD in cross-sectional studies (Higuchi, Kabeya, and Kato ([2017](#ref-higuchi17)); Kim et al. ([2017](#ref-kimVisceralObesityAssociated2017)); Lampe, Zhang, et al. ([2019](#ref-lampeVisceralObesityRelates2019)); Morys, Dadar, and Dagher ([2021](#ref-morysAssociationMidlifeObesity2021)); Veldsman et al. ([2020](#ref-veldsman20)); Vuorinen et al. ([2011](#ref-vuorinenChangesVascularRisk2011)); Yamashiro et al. ([2014](#ref-yamashiroVisceralFatAccumulation2014))). Mendelian randomization suggested that larger abdominal fat depots (measured as waist-to-hip ratio) are more predictive for WMH than overall obesity (measured as body mass index) ( Marini, Anderson Christopher, and Rosand ([2020](#ref-mariniGeneticsCerebralSmall2020))). This effect was largely independent of DBP and glucose metabolism. Along these lines, several studies reported an association between abdominal obesity and WMH in deep white matter regions as opposed to hypertension-related periventricular WMH, hinting to the involvement of different pathophysiological mechanisms (Armstrong et al. ([2020](#ref-armstrongCommonGeneticVariation2020)); Griffanti et al. ([2018](#ref-griffanti18)); Lampe, Zhang, et al. ([2019](#ref-lampeVisceralObesityRelates2019)); Veldsman et al. ([2020](#ref-veldsman20))). One of those mechanisms might be the circulation of systemic inflammatory markers, secreted by abdominal fat tissue, which initiate pathological processes such as endothelial damage and blood brain barrier leakage in the cerebral vasculature of the deep white matter (Wardlaw, Smith, and Dichgans ([2019](#ref-wardlaw19))). Yet, longitudinal evidence is scarce and the RUN-DMC study showed that while high baseline waist circumference predicted stronger increase in WMH from baseline to follow-up, no predictive effects of continuous waist circumference or body mass index on cross-sectional or longitudinal WMH were found (Arnoldussen et al. ([2019](#X7e74b322196fb7da72135ed9df16bfcb333c5a4))). Thus, the impact of abdominal obesity on WMH progression remains to be established.   
Self-identified gender, which is assessed in most studies using self-reported binary categories and often misinterpreted as (biological) sex, is another important predictor of WMH. In population-based studies, women tend to show larger and more severe WMH (De Leeuw et al. ([2001](#ref-deleeuwPrevalenceCerebralWhite2001)); Fatemi et al. ([2018](#Xd342f39fcc533eb0d8182b542cbfdfb7ee67fbe)); P. S. Sachdev et al. ([2009](#ref-sachdev09))) while in hospital-based studies, men are overrepresented and show severe cSVD (with stroke or cognitive presentation) more often (Jiménez-Sánchez et al. ([2021](#ref-jimenez-sanchez21))). Women and men differ in their vascular risk factor profile, e.g. the incidence of smoking and hypertension tends to be higher in men, while women tend to develop a more unfavorable abdominal fat distribution after menopause. Additionally, the neuroprotective effects of estrogens are reduced after menopause which might contribute to increased susceptibility of women to neurovascular degeneration and dementia (Dufouil, Seshadri, and Chene ([2014](#ref-dufouilCardiovascularRiskProfile2014))). We therefore hypothesized that higher blood pressure and abdominal obesity might be more strongly associated with WMH progression in women compared to men. Yet, while WMH have been associated with decline in executive function and other cognitive domains in older adults, their importance for gender-specific cognitive performance is unclear (Kynast et al. ([2018](#Xffa50fa58953281a41b0e51d7492e430240fe37))). Women have previously not performed worse in cognitive tests despite having higher WML load (P. S. Sachdev et al. ([2009](#ref-sachdev09))). Therefore, WMH progression might be less negatively associated with cognitive performance in women compared to men.   
Few studies to date have reported sex/gender-stratified data regarding the association of vascular risk factors and WML, as well as WMH and cognitive outcomes. This ‘gender data gap’ hampers a better understanding of gender-specific risks and potential prevention strategies.   
Here, we therefore aim to replicate previous findings on the relationship of higher blood pressure, more WMH progression and worsening of cognitive function in a large cohort of population-dwelling older adults. In exploratory analyses we aim to extend these findings towards abdominal obesity, a risk factor which has been understudied in longitudinal designs. We will explore gender-by-risk factor interactions for WMH progression and gender-by-WMH progression interaction for cognitive outcomes. We will also report gender-stratified results for both risk factors if no interaction appears.

# Aims and hypotheses

## Confirmatory analyses

Based on the literature and power analyses, we will perform replication analyses for the following hypotheses:

* H1: Higher DBP at baseline predicts stronger increase of WMH volume at follow-up.
* H2: Stronger WMH progression is associated with stronger decline in executive cognitive function.
* H3: Stronger WMH progression is associated with stronger decline in global cognitive function.

## Exploratory analyses

We will test the following hypotheses in exploratory analyses. These may be underpowered.

* E1a: Higher WHR at baseline predicts stronger increase of WMH volume at follow-up.
* E1b: Higher change in WHR predicts stronger increase of WMH volume at follow-up.
* E1c: Higher change in DBP predicts stronger increase of WMH volume at follow-up.
* E2a: WMH progression is more pronounced in women.
* E2b: There is an interactive effect of gender and DBP on WMH progression, where in women DBP has a stronger effect than in men.
* E2c: There is an interactive effect of gender and WHR on WMH progression, where in women WHR has a stronger effect than in men.
* E3a: There is an interactive effect of gender and WMH progression on executive cognitive function where in women WMH progression is associated with less decline in executive cognitive function.
* E3b: There is an interactive effect of gender and WMH progression on global cognitive function where in women WMH progression is associated with less decline in global cognitive function.

If the interactions are not significant, we will report gender-stratified results according to the SAGER guidelines (Heidari et al. ([2016](#ref-heidariSexGenderEquity2016))).  
Finally, we will explore the spatial distribution of incident WMH depending on the risk factor profile and test the mediating effects of WMH on the association of vascular risk factors and cognitive function. For a summary table of planned analysis, see Table number missing.

# Methods

## Existing data

This project is an analysis in the LIFE-Adult study sample, a longitudinal, two-wave, population-based study conducted in the city of Leipzig, Germany from 2011 until 2021. Baseline characteristics of the LIFE-Adult sample (Loeffler et al. ([2015](#ref-Loeffler_2015))), the baseline association of hypertension and WHR with voxel-wise WMH volume (Lampe, Zhang, et al. ([2019](#ref-lampeVisceralObesityRelates2019))) and the cross-sectional link between WMH volume and different cognitive domains (Lampe, Kharabian-Masouleh, et al. ([2019](#ref-lampeLesionLocationMatters2019))) in this sample have been previously published. At the time of this stage-1 protocol, we have access to the baseline anthropometric and medical data and have preprocessed and quality-controlled the imaging data of both time points (bias control level 2). We have not gained access to the follow-up anthropometric, medical and cognitive data and have not explored any associations of these measures with WMH volume beyond the baseline investigations cited above.

## Data Availability Plan

Due to potential identifiability of individuals from demographic and medical information, we will share a surrogate version of the dataset on [https://github.com/fBeyer89/VRF-and-progression-of-WMH](https://github.com/fBeyer89/VRF-and-progression-of-WML) along with the analysis code (Nowok, Raab, and Dibben ([2016](#ref-nowokSynthpopBespokeCreation2016))). Statistical maps from whole-brain analysis will be published on NeuroVault. Raw data of the LIFE-Adult cohort can be requested via the LIFE data center (<https://ldp.life.uni-leipzig.de/>).

## Ethics Statement

The LIFE-Adult study has been approved by the ethics committee of the University of Leipzig and was conducted according to the declaration of Helsinki. All participants gave written informed consent.

## Data collection and preparation

This project is part of a larger population-based epidemiological study LIFE-Adult. LIFE-Adult has investigated 10.000 individuals from the Leipzig area, who underwent genotyping and deep phenotyping at up to two time points (including extensive questionnaires, MRI and cognitive testing in a subgroup of N ~ 2700). Recruitment and inclusion criteria as well as more information on the study design and objectives can be found in (Loeffler et al. ([2015](#ref-Loeffler_2015)); Engel et al. ([2022](#ref-engelCohortProfileLIFEAdultStudy2022))). Baseline assessments took place from 2011 to 2014 and the follow-up visits were scheduled between 2017 to 2021. For the follow-up visit, participants from the LIFE-Adult MRI cohort (Nbaseline = ~2700) were re-invited to participate in medical assessments, cognitive testing and MRI scanning. In total, 1077 participants underwent MRI at follow-up. For this analysis, we will include all participants who were aged between 45 and 85 years at the baseline assessment based on recent studies showing WMH volume to increase from the fifth life decade on (d’Arbeloff et al. ([2019](#X68d9f7f5c84b9bfa7d6c00be35ab8bb772c5487)); Wen et al. ([2009](#ref-wenWhiteMatterHyperintensities2009))). All included participants were scanned twice with a mean time between scans of 6 years (standard deviation=1.9 years).

## Anthropometrics

Waist and hip circumferences were taken by trained study staff using an ergonomic circumference measuring tape (SECA 201) to the nearest 0.1 cm at baseline and follow-up. WHR was calculated by dividing waist by hip circumference. We will use baseline WHR and change in WHR, calculated as difference between follow-up and baseline (i.e. WHR\_change = WHR\_followup – WHR\_baseline), as independent variables of interest.

## Blood pressure

Diastolic blood pressure was measured three times at 3-min intervals using an automatic oscillometric blood pressure monitor (OMRON 705IT, OMRON Medizintechnik Handelsgesellschaft mbH) in participants seated for at least 5 minutes at baseline and followup. We will calculate the average of the three DBP measurements for our analysis. We will use baseline DBP and change in DBP, calculated as difference between follow-up and baseline (i.e. DBP\_change = DBP\_followup – DBP\_baseline), as independent variables of interest.

## Cognitive Assessment

In both LIFE-Adult assessments, participants underwent the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) -plus test-battery, an established set of neurocognitive tests designed to detect early cognitive changes related to Alzheimer’s disease (AD) (Morris et al. ([1989](#ref-Morris_1989))). The applied version additionally includes the Trail-Making-Test (TMT) and phonemic fluency (S-words) to assess executive function and verbal fluency independent of semantic memory. We will derive a composite score of executive function and a global cognitive score similar to previous studies (Beyer et al. ([2017](#ref-beyerHigherBodyMass2017)); Kharabian Masouleh et al. ([2016](#ref-kharabianmasoulehHigherBodyMass2016)); Oosterman et al. ([2010](#Xe2487de4cad9c9b7d43723f18c72a0693242cd8))). The executive function summary score will be calculated as sum of z-scored time to complete TMT part B over time to complete TMT part A , phonemic and semantic fluency (verbal fluency). Z\_exec = [– z (time for TMT part B/time for TMT part A)+ z\_phonemic fluency + z\_semantic fluency]/3 The global score will be based on the executive function score, processing speed and a composite memory score. The processing speed score is given by the Z-scored negative value of the time taken to complete part A. Z\_processing\_speed = -z(TMT time for part A). For the memory score, we will use learning, recall and recognition from the CERAD word list. Learning will be defined as the sum of three consecutive learning trials of the CERAD word list (10 words), recall as the sum of correctly recalled words after a delay, in which participants performed a nonverbal task, and recognition as the number of correctly recognized words out of a list of 20 presented afterwards. Z\_memory = (z\_sum\_learning + z\_recall + z\_recognition)/3 The global cognitive performance score was derived by summing up the z-scores from all four domains: Z\_global\_cognition = Z\_exec + Z\_proc + Z\_memory/3 All individual sub-scores will be Z-scored across timepoints prior to creating composite scores. The composite scores for executive function and global cognition will again be Z-scored.

## Imaging acquisition and preprocessing

At baseline and follow-up, anatomical and lesion-sensitive imaging was acquired on a 3T MAGNETOM Verio scanner (Siemens, Erlangen, Germany) with a 32-channel head coil. Anatomical imaging was done with a T1-weighted magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence with the following parameters (flip angle = 9 degrees,relaxation time [TR] = 2,300 ms, inversion time [TI] = 900 ms, echo time [TE] = 2.98 ms, 1-mm isotropic resolution, acquisition time [AT] = 5.10 minutes), and the lesion-sensitive imaging was performed with a fluid-attenuated inversion-recovery (FLAIR) sequence (TR = 5,000 ms, TI = 1,800 ms, TE = 395 ms,1 × 0.49 × 0.49 mm resolution, AT = 7.02 minutes).

## Lesion Segmentation

The longitudinal pipeline of the Lesion Segmentation Toolbox (version 3.0.0, run on MATLAB version 9.10) was used to estimate WMH progression (P. Schmidt and Wink ([2017](#ref-schmidtLSTLesionSegmentation2017))). This pipeline estimates the location of stable lesions as well as regression and progression of lesions over time (Schmidt et al. 2019). First, we performed cross-sectional lesion segmentation using the Lesion Prediction algorithm with its default parameters. Then, we applied the longitudinal pipeline to the cross-sectional runs and obtained voxel-wise maps of lesion change (LCL maps). In these three-valued whole-brain maps, 1 indicates a regression of lesion volume, 2 indicates a stable lesion and 3 indicates a newly appeared lesion in this voxel. For baseline lesion volume, we summed up the volume of all LCL voxels with a value of 2 and for follow-up lesion volume, we added the volumes of all LCL voxels with a value of 1 (regressed lesion voxels) or 3 (novel lesion voxels). For our analysis, we will calculate asinh-transformation of baseline WMH volume (asinh(WMLBL))and change as difference of asinh-transformed WMH volume at follow-up and baseline (WMLchange=asinh(WMLFU)-asinh(WMLBL)) to achieve a normal distribution of regression residuals. During visual quality control, we checked whether the lesions marked in the LCL were confounded due to poor scan quality, lesion regression or brain pathologies at baseline or follow-up. We gave the following LCL quality ratings: issues with MRI data quality, e.g. due to motion (LCL quality =1), ventricular expansion which led to regression of lesion voxels in some cases (LCL quality =2) and brain pathologies such as stroke or congenital lesions (LCL quality =3).

## Anatomical Preprocessing

T1-weighted imaging was processed with the longitudinal stream of FreeSurfer version 5.3.0 to derive estimated total intracranial volume (TIV) (Reuter 2012). We will z-score the value to achieve more stable model fitting.

### Medical, demographic and questionnaire data

Participants were asked to report previous cardiovascular and other diseases as well as the intake of medication. Self-reported medication was classified according to the Anatomical Therapeutic Chemical (ATC) Classification System. The intake of anti-hypertensive medication will be defined based on self-reported intake of hypertensive medication in the cardiological questionnaire or the intake of anti-hypertensive medication based on the list of medication (see Supplementary Table 9). Here, we will use ATC codes starting with “C02,”C03”, “C07”, “C08”, “C09” as indicators of anti-hypertensive medication. The use of centrally active medication will be defined based on the self-reported intake of medication with the ATC codes M03B (muscle relaxants, centrally acting agents), N02A (opioids), N03 antiepileptics, N04 anti-parkinson drugs, N05 psycholeptics, N06A antidepressants, N06B psychostimulants, agents used for ADHD and nootropics, N06D anti-dementia drugs (except for N06Dx02, ginkgo folium) or N07A parasympathomimetics (see Supplementary Table 9). Participants underwent the SIDAM (structured interview for the diagnosis of dementia) which includes the Mini Mental State Examination (MMSE) at baseline and follow-up. Self-reported level of education will be dichotomized into a binary variable indicating the attainment of tertiary education (Lampert et al. ([2013](#Xd13565ceb182e176f6836a3c359ffc1a8144c53))). We will use 3.6 as cut-off. Education was only assessed at baseline. For the assessment of depressive symptoms, participants filled in the German version of the Center for Epidemiological Studies-Depression scale at baseline and follow-up. We will derive the summary score ranging from 0 to 60.

## Data exclusion

We will exclude participants with neurological or psychiatric disease at baseline or follow-up (i.e. radiological finding of ischemic, traumatic or hemorrhagic lesion in MRI, incidental finding leading to non-usability of participant, multiple sclerosis, Parkinson’s disease, epilepsy, previous stroke, self-reported dementia, intake of centrally active medication or a score of < 24 in the MMSE, see Supplementary Table 9). If participants lack information on these variables for one or both timepoints, we will not exclude the participant. Only participants with complete longitudinal WMH data will be included. Further, participants for whom the Lesion Segmentation Toolbox did not run correctly or who were labeled to have poor scan quality or brain pathologies (LCL quality = 1 or 3 ) during quality control will be excluded from all analyses (H1 – H3 and exploratory analyses). Timepoints with extreme outliers in TMT A (time to complete over 300 s) and B (time to complete over 300s) will not be considered in the analysis of executive function score (H2). Participants who miss WHR or DBP or have biologically implausible values (see below) at baseline and follow-up are excluded from the analysis. Otherwise, biologically implausible values in waist-to-hip ratio (<0.5 or >1.5) or blood pressure (DBP>140 mmHg and SBP<DBP) will be imputed (see below).

## Missing data

### Dependent variables

Only participants with complete and usable WMH data at both time points will be investigated. If participants miss data on any of the cognitive tests (e.g. TMT, semantic or phonemic fluency, CERAD word list), we will construct the executive function and global composite score from the remaining tests. If participants do not have data on any test for executive function (i.e. no data on TMT, phonemic or semantic fluency) or global composite score (i.e. no cognitive data at all) for both timepoints, they will be excluded for the respective analyses. Otherwise, default listwise deletion of the respective time point will be performed in the mixed models.

### Independent variables

If participants are missing WHR or DBP at only one occasion, we will impute the missing value. If participants miss the measures or have biologically implausible values (see above) at both time points, they will be excluded from the analysis.

### Covariates

If participants are missing information on education (assessed only at baseline), hypertensive treatment, CES-D at one or both time points or TIV we will impute the missing values.

### Imputation

Multi-level Imputation will be performed with the R package mice 3.9.0 for education, TIV, DBP, WHR, CESD and hypertensive treatment (see prepare\_data.R on github). The imputation will be based on all available cases after applying exclusion criteria and will be repeated 5 times with 10 iterations. We will report the percentage of missing data for each of the variables. Imputation methods for education and TIV (2nd level variables) will be “2l.bin” and “2lonly.pmm”, and for DBP, WHR, CESD and hypertensive treatment we will use “2l.pan”. See below for the variables used for the imputations.

### Power Calculation

##### Power calculation for Model M1

We performed a power calculation by simulating the effects of interest based on LIFE-Adult baseline data and previous studies. All code can be found on <https://github.com/fBeyer89/VRF-and-progression-of-WML>.

We simulated individual data points based on three components: cross-sectional variation, longitudinal variation and error terms.  
We based the cross-sectional variation on the baseline associations of age, gender, systolic blood pressure (SBP), WHR with WMH in LIFE-Adult participants over 50 years. We used systolic blood pressure but effects have been shown to be similar or more pronounced for DBP. First, we fitted the predictors to the baseline WMH load using a log-linked GLM from the Gamma family.

The advantage of this approach is that we can use these coefficients to estimate WMH load in its original unit (cm³) and thus combine cross-sectional effects with longitudinal effect sizes from the published literature. Then, we drew random samples from a multivariate normal distribution of age, gender, SBP, WHR and ICV with the same mean and covariance matrix as in the baseline data. Using the coefficients derived from the GLM and the simulated predictors, we calculated baseline estimates of WMH in cm³ .  
The longitudinal effect of elapsed time on WMH was based on eight epidemiological and interventional studies in older adults (age > 60 years) (de Havenon et al. ([2019](#ref-dehavenonBloodPressureGlycemic2019)); Dickie et al. ([2016](#ref-dickieProgressionWhiteMatter2016)); Godin et al. ([2011](#ref-godin2011antihypertensive)); Nasrallah et al. ([2019](#ref-nasrallahAssociationIntensiveVs2019)); Scharf et al. ([2019](#X003ff1da26a04bcfbabaa823ebecda1d16bd31e)); R. Schmidt et al. ([2005](#ref-schmidtWhiteMatterLesion2005)) Peng et al. ([2014](#ref-peng14))). The weighted average annual change in WMH based on these studies was 0.64 cm³. As the prevalence of risk factors (hypertension, diabetes) and mean age varies across these studies, an average WMH annual change of 0.64 cm³ is likely to overestimate the isolated effect of time on WMH. Further, most studies reported the estimates in units of cm³ from linear models without considering the strongly skewed distribution of WMH volume, and are thus biased. For a more conservative estimate, we based the individual change in WMH from baseline to follow-up on a normal distribution with the mean at the half of the estimated WMH annual change (0.32 cm³/y) and a relatively low standard deviation of 0.1 cm³, reflecting the fact that elapsed time is overall positively associated with the progression of WMH. If values of age-related WMH change below zero were drawn, they were set to 0.01.

The modifying effect of baseline SBP and change in SBP on age-related change in WMH load was based on four epidemiological studies by (Dickie et al. ([2016](#ref-dickieProgressionWhiteMatter2016)); Godin et al. ([2011](#ref-godin2011antihypertensive)); Gottesman Rebecca et al. ([2010](#X04b1bfdb5a901278972f24e35d623eb45594b53)); Verhaaren et al. ([2015](#X789dab840521e5916f8858d9d9c2056329a39b8))). For baseline SBP, the average modifying effect of 1 mmHg average SBP was 0.0052 cm³/y. We used a standard deviation of 0.001 cm³/y to draw change estimates due to baseline SBP from a normal distribution. The effect of change in SBP could be drawn from only one study (Godin et al. ([2011](#ref-godin2011antihypertensive))) and was 0.0025 cm³/y per mmHg. Again, we used a normal distribution with a standard deviation of 0.001 cm³/y.  
Previous longitudinal studies did not investigate baseline WHR as a predictor of WMH progression. Studies on BMI either reported no effect (Dearborn et al. ([2015](#ref-dearbornObesityInsulinResistance2015)); Scharf et al. ([2019](#X003ff1da26a04bcfbabaa823ebecda1d16bd31e))) or did not show quantitative effect sizes (Gustafson et al. ([2004](#ref-gustafson24yearFollowupBody2004)); Vuorinen et al. ([2011](#ref-vuorinenChangesVascularRisk2011))). Yet, cross-sectional studies indicate that WHR is associated with WMH, predominantly in deep WM (Alqarni et al. ([**2020**](#ref-alqarniSexDifferencesRisk2020)); Griffanti et al. ([2018](#ref-griffanti18)); Higuchi, Kabeya, and Kato ([2017](#ref-higuchi17)); Kim et al. ([2017](#ref-kimVisceralObesityAssociated2017)); Lampe, Zhang, et al. ([2019](#ref-lampeVisceralObesityRelates2019)); Morys, Dadar, and Dagher ([2021](#ref-morysAssociationMidlifeObesity2021)); Veldsman et al. ([2020](#ref-veldsman20))). Thus, while there is little longitudinal data to rely on, based on cross-sectional reports we expect a smaller effect size for WHR compared to blood pressure.  
We obtain an exploratory estimate of the effect size by comparing the baseline association in the LIFE-Adult cohort of SBP and WHR with asinh-transformed WMH volume. Here, the coefficients are 0.84 (asinh(cm³))/WHR unit and 0.0083 (asinh(cm³)/mmHg) for WHR and SBP, respectively. We use the approximation that the interaction effect of WHR on age change would be similar to the interaction effect of SBP (0.0052 cm³/y), scaled by their ratio, leading to an interaction effect of WHR of 0.0052cm³/y/mmHg \* 0.84/0.0083 = 0.53 cm³/y. This approach is not ideal as it combines effect sizes from the literature referring to raw WMH units (cm³) with relationship of effects on log-scaled data. Yet, it is the best we can do given the lack of appropriate data on the expected effect size.  
In our simulations, we will thus estimate the power for a range of scales of this exploratory effect size (0.5, 1, 1.5 times 0.53 cm³/y). We will use the same values for the effect of change in WHR. Change in SBP and WHR from baseline to follow-up were based on published results in epidemiological studies of aging (Baltimore Longitudinal Study of Aging (BLSA) and Whitehall II). Average time between both assessments in LIFE-Adult was 6.7 years.  
We estimated the average change in SBP to be: 0.76 mmHg/y (averaged over BLSA: 8.5 mmHg/decade for men, 4.4. mmHg/decade for women at age 60 and Whitehall 2: 1 mmHg/y for older men/women (60 - 70 years) (Dearborn et al., 2015; Wills et al., 2011). We thus drew the change in SBP from a normal distribution with a mean of 0.76 mmHg/y \* 6.76y = 5.13 mmHg and arbitrary, yet relatively high standard deviation of 4 mmHg. For WHR, (Shimokata et al., 1989) reported an increase of WHR of 0.0073 in men, 0.0021 in women over 5 years. Thus, WHR change was taken from a normal distribution with a mean of 0.0047/5 6 0.0056 and a similarly high standard deviation of 0.005.  
For the error terms, we used a subject random effect with a mean of zero and a standard deviation of 0.5 cm³, while for the random error we used a normal distribution around zero with 1cm³ standard deviation.  
Finally, all effects were added according to  
*WMH=*  
*exp(age\_sim\*coeff\_age + ….)* (cross-sectional effects from Gamma-loglink GLM)  
*+(effect\_age\_change+((effect\_SBP\_baseline\*SBP\_baseline)+(effect\_WHR\_baseline\*WHR\_baseline)\*age\_change)*( effects of elapsed time/change in age, modified by baseline SBP and WHR )  
*+ WHR\_change*effect\_WHR\_change + SBP\_change*effect\_SBP\_change* (effects of change in SBP and WHR)  
*+ random\_effect + residual\_error* (residual error and random effects)\*

Then, we repeated the simulation 50 times for four sample sizes (N=400,600,800,1000) and for three scaling factors of WHR effects (0.5, 1, 1.5). We used the asinh-transform and fitted the linear mixed model M1. We extracted p-values for the interaction effects of SBP baseline, and WHR baseline on the age change effect, as well as the effects of SBP and WHR change, and considered p<0.033 as significant. Then, we derived the power by calculating the number of rejected null hypotheses compared to the total number of tests. If the average effect size across simulations was not in the expected direction (positive for all four predictors), we assigned a power of 0. We also extracted the average Bayes Factor and one-sided Bayes Factor (based on 10 Markov chains to calculate proportion of posterior estimates in the hypothesized direction).

We thus conclude that after applying exclusion criteria to our sample of N ~ 1000 individuals, we will able to detect the interaction of DBP with age change with a power > 0.9 and a Bayes factor > 10. We are not sufficiently powered to detect the hypothesized effect size of baseline WHR on WMH progression. We thus report these results in the exploratory analysis section. Similarly, we are not sufficiently powered to detect effects of change in DBP and WHR on WMH progression and will also report these results in the exploratory analysis section.

### Power calculation for Model M2 and M3

A negative effect of WMH progression on executive and global cognitive function is well established in non-clinical populations (Debette et al. ([2019b](#Xdc21d2763dcaad49bb7521006589a3de0f43fac)); O. K. L. Hamilton et al. ([2021](#X6debfffe7c91874d519217e7490dd93aec96bf6)); Kloppenborg et al. ([2014](#X6c46b7734a36ad0b148dd2439f1429135d34f40))).  
Unfortunately, effect sizes for WMH progression have rarely been reported in quantitative units but have been calculated for semi-quantitative ratings or dichotomized quantitative outcomes.  Thus, we base the following power analysis on a recent investigation in 540 members of the Lothian Birth cohort (average age: 72.6 years) over nine years (O. K. L. Hamilton et al. ([2021](#X6debfffe7c91874d519217e7490dd93aec96bf6))).  
Here, the ratio of WMH load normalized by TIV predicted a decline in global cognitive function (standardized β = −0.149 ) and processing speed (standardized β = −0.176).  
As our cohort is younger on average than the Lothian Birth cohort, we expect the effect size to be smaller, yet still reliable. Using the pwr package in R, we estimate a minimum number of 850 participants to detect a small negative effect of WMH volume on cognitive function (standardized β = −0.1; pwr.r.test(r=-0.1, sig.level=0.05, power=0.9, alternative=“less”)) and a minimum number of 590 participants for a slightly larger effect (standardized β = −0.12; pwr.r.test(r=-0.1, sig.level=0.05, power=0.9, alternative=“less”)).  
Our power should thus be sufficient to detect the effect on global and executive cognitive function in our cohort.

# Statistical Analysis

## Confirmatory Analyses

Statistical analyses scripts can be inspected on <https://github.com/fBeyer89/VRF-and-progression-of-WML>. All statistical analysis with WMH volume or executive function as dependent variable will be performed in R version 4.2.2. We will use linear mixed models implemented in lmerMod (lmerTest) and BayesFactor version 0.9.12-4.2 (generalTestBF) with subject as a random intercept (see function run\_LME\_realdata.R on github).  
More specifically, we will test 3 models for our four hypotheses (see Table 8).

M1: asinh(WMH) ~ Age\_baseline + Age\_change + DBP\_baseline + DBP\_baseline:Age\_change + DBP\_change + WHR\_baseline + WHR\_baseline:Age\_change + WHR\_change + gender + HT\_medication + TIV + (1|subj)

M2: Z\_Exec ~ Age\_baseline + Age\_change + asinh(WMH)\_baseline + Age\_change :asinh(WMH)\_baseline + WMH\_change + gender + education + CES\_D

M3: Z\_global\_cog ~ Age\_baseline + Age\_change + asinh(WMH)\_baseline + Age\_change :asinh(WMH)\_baseline + WMH\_change + gender + education + CES\_D

### Explanation of covariates (M1)

* Age\_baseline: effect of age at baseline
* Age\_change: effect of passed time between baseline and follow-up (progression)
* DBP\_baseline: effect of baseline DBP
* DBP\_baseline: modifying effect of baseline DBP on progression of WMH between baseline and follow-up (effect of interest for H1)
* DBP\_change: effect of change in DBP between baseline and follow-up on WMH progression (effect of interest for E1c)
* WHR\_baseline effect of baseline WHR
* WHR\_baseline:Age\_change: modifying effect of baseline WHR on progression of WMH between baseline and follow-up (effect of interest for E1a)
* WHR\_change: effect of change in WHR between baseline and follow-up on WMH progression (effect of interest for E1b)
* Gender: adjust for gender (no power analyses possible for gender/sex interaction, therefore we control for it in confirmatory analyses)
* HT\_medication: adjust for hypertension medication as this probably influences the effect of DBP on WMH progression
* TIV: total intracranial volume, trivially linked with WMH volume

### Explanation of covariates (M2 & M3)

* Age\_baseline: effect of age at baseline
* Age\_change: effect of passed time between baseline and follow-up (progression)
* asinh(WMH)\_baseline: effect of baseline WMH volume
* Age\_change :asinh(WMH)\_baseline: modifying effect of baseline WMH load on cognitive function changes between baseline and follow-up
* WMH\_change: effect of interest M2/M3: effect of WMH progression on cognitive function changes
* Gender: adjust for gender (no power analyses possible for gender/sex interaction, therefore we control for it in confirmatory analyses)
* Education: adjust for education level as it probably influences overall cognitive performance
* CES-D: adjust for depressive symptoms as they influence overall cognitive performance

## Inference criteria

We will base our inference on frequentist and Bayesian full null model comparison. For frequentist statistics, we used the two-sided p-value for the fixed effects calculated in lmerTest using Satterthwaite’s denominator degrees of freedom. *.*Additionally, we applied a multivariate Wald test implemented as D1 in mice to compare models with and without the terms of interest age x DBP baseline and WMH change for multiple imputations.As we have directed hypotheses, we will use one-sided p-values (αTwoSided = 2 \* αOneSided). We will Bonferroni-adjust for 3 tested hypotheses by dividing the alpha-level of 0.05 by 3 (αOneSided < 0.05/3). Practically, we will use αTwoSided =2\* αOneSided /3 = 0.033 as threshold on the two-sided p-values we receive from lmerTest and D1.*.* To obtain Bayes Factors, we will fit generalTestBF with the options whichModels="top", multicore = T, neverExclude = c("age\_base", "^age\_change$", "^DBP\_base$", "^WHR\_base$", "gender", "icv", "id") to the data. Subject is defined as a random effect and we will use the software’s default priors (i.e. JZS prior with a Cauchy prior on effect size and the Jeffreys prior on variance). We will extract Bayes Factors for the full model compared to models omitting the independent variables of interest. We will calculate one-sided Bayes factors by drawing from the posterior distribution 10 times and calculating the probability of finding the effect in the expected direction. Then, we will multiply the two-sided Bayes factor with this probability divided by 0.5 which represents equal likelihood of both directions (see <https://gist.github.com/richarddmorey/7c1bd06a14384412f2145daee315c036> for an example). We will pool the Bayes factors by calculating the average and report the range of obtained Bayes factors from the five imputed datasets.  
We will interpret a Bayes Factor between 3 and 6 as moderate evidence, and a Bayes factor between 6 and 10 as positive evidence and above 10 as strong evidence in favor of the predictor. A Bayes Factor between 1/3 and 3 is deemed indecisive and a Bayes Factor smaller than 1/3 and 1/6 as moderate/strong evidence in favor of the null hypothesis. Bayes Factors will not be corrected for multiple comparisons as they inherently provide a lower false positive rate.  
Taken together, we will reject the null hypothesis if p<0.033 and BF>3. We will accept the null hypothesis if p>0.033 and BF < 1/3 (see supplementary Table 8).

## Transformations & Checking of Assumptions

All assumptions for LME will be checked separately for the five imputed datasets (function test\_LME\_assumptions.R on github).

### Normality and homoscedasticity of residuals

We will inspect the normality and homoscedasticity of residuals using qq-plots and plots of fitted vs. residual values. Given the known skewness of WMH volumes, we will transform this measure using asinh-transformation as described above. The advantage of this transform is that it is also valid for zeros. We will perform asinh transformation of CESD for M2 and M3.  
If for M1, the residuals are not normally distributed for all five imputed datasets, we will implement a generalized linear mixed model, using a Gamma error function and log link function instead of a linear mixed model. Here, we will use the raw WMH volumes as outcome. We fit a robust LMM for all models M1 – M3 to evaluate their robustness

### Normality of random effects

We visually inspect the required normal distribution of the random effects.

### Influential cases

We will use the function ‘influence’ from the influence.ME package to assess influential cases. We will plot Cook’s distance for each model, and define outliers as those cases with Cook’s distance > μ + 3 σ. We will re-calculate all models without influential cases, and report Bonferroni-corrected p-values of these models if they lead to a different conclusion than the original models for any of the imputations.

### Model stability

We will test the stability of the linear mixed model with the command “glmm.model.stab” based on code written by Roger Mundry (<https://github.com/keyfm/eva/blob/master/trpm8/src/glmm_stability.r>.). This function derives coefficients and their standard errors for all predictors while excluding levels of the random effects one at a time. If the function returns convergence issues, we will try to fix them by introducing a control object. Further, we will inspect the summarized range of estimated coefficients and evaluate whether they differ substantially from the original coefficients.

### Variance inflation

We will calculate variance inflation with the function ‘vif’ from the car package omitting the random effect and interaction terms from the mixed models M1 - M4. A VIF above 10 will be considered problematic and lead to the inspection of a correlogram of all variables in the model. If two variables of interest are highly collinear, we will calculate the residualized version of each of the predictors to infer its independent effect. If two control variables are highly collinear, we will ignore their covariance.

## Exploratory Analyses

* E1: Effects of baseline WHR and change in risk factors on WMH progression Our power analysis revealed low power to detect the hypothesized effect size for the association with baseline WHR as well as change in blood pressure and WHR on WMH. There is very little data from longitudinal studies and our estimate was based on scaling of cross-sectional associations which might be biased and error-prone. We therefore test these effects in exploratory analyses:
* E1a: Higher WHR at baseline predicts stronger increase of WMH volume at follow-up.
* E1b: Higher change in WHR predicts stronger increase of WMH volume at follow-up.
* E1c: Higher change in DBP predicts stronger increase of WMH volume at follow-up.

We will use the statistical model M1

M1: asinh(WMH) ~ Age\_baseline + Age\_change + DBP\_baseline + DBP\_baseline:Age\_change + DBP\_change + WHR\_baseline + WHR\_baseline:Age\_change + WHR\_change + Gender + HT\_medication + TIV + (1|subj)

and report the effect size, p-value and one-sided Bayes factor for the interaction term of baseline WHR and age change, DBP change and WHR change.

## E2: Gender-specific effects in WMH progression

We did not perform power analyses for these hypotheses (E2a - E2c) due to missing reference values in the literature. Therefore, we will explore whether WMH progression is more pronounced in women (E2a). We will use a modified version of statistical model M1

M1E2a: asinh(WMH) ~ Age\_baseline + Age\_change + Gender + Gender:Age\_change + DBP\_baseline + DBP\_baseline:Age\_change + DBP\_change + WHR\_baseline + WHR\_baseline:Age\_change + WHR\_change + HT\_medication + TIV + (1|subj)

and report the effect size, p-value and one-sided Bayes factor for the interaction term of gender and age change. We expect a positive coefficient for women.

We will also explore whether there is an interactive effect of gender and DBP on WMH progression, where in women DBP has a stronger effect than in men (E2b). We will use a modified version of statistical model M1

M1E2b: asinh(WMH) ~ Age\_baseline + Age\_change + Gender + Gender:Age\_change + Gender:DBP\_baseline + Gender:Age\_change:DBP\_baseline + DBP\_baseline:Age\_change + DBP\_change + WHR\_baseline + WHR\_baseline:Age\_change + WHR\_change + HT\_medication + TIV + (1|subj)

and report the effect size, p-value and one-sided Bayes factor for the three-way interaction term of gender, age change and DBP\_baseline. We expect a positive coefficient for women.

We will test whether there is an interactive effect of gender and WHR on WMH progression, where in women WHR has a stronger effect than in men (E2c).

M1E2c: asinh(WMH) ~ Age\_baseline + Age\_change + Gender + Gender:Age\_change + Gender:WHR\_baseline + Gender:Age\_change:WHR\_baseline + DBP\_baseline:Age\_change + DBP\_change + WHR\_baseline + WHR\_baseline:Age\_change + WHR\_change + HT\_medication + TIV + (1|subj)

and report the effect size, p-value and one-sided Bayes factor for the three-way interaction term of gender, age change and WHR\_baseline. We expect a positive coefficient for women.

## E3: Gender-specific effects of WMH progression on cognitive function

Regarding cognitive function we will explore if there is an interactive effect of gender and WMH progression on executive cognitive function where in women WMH progression is associated with less decline in executive cognitive function (E3a). We will use a modified model of M2

Z\_exec ~ asinh(WMH)\_baseline + WMH\_change + Gender:WMH\_change + Age\_baseline + Age\_change :asinh(WMH)\_baseline + Age\_change + Gender + education + CESD + (1|subj)

and report the effect size, p-value and one-sided Bayes factor for the interaction term of gender and WMH change. We expect a positive coefficient for women.

Finally, we will test if there is an interactive effect of gender and WMH progression on global cognitive function where in women WMH progression is associated with less decline in global cognitive function (E3b).  
We will use a modified model of M3

Z\_globalcog ~ asinh(WMH)\_baseline + WMH\_change + Gender:WMH\_change + Age\_baseline + Age\_change :asinh(WMH)\_baseline+ Age\_change + Gender + education + CESD + (1|subj) and report the effect size, p-value and one-sided Bayes factor for the interaction term of gender and WMH change.

We expect a positive coefficient for women.

## Analyses of SBP and WMH progression

We repeated model M1 using baseline SBP and change in SBP as predictor. We aimed to see whether changes in SBP would have a similar effect.  
We performed the same imputation procedure as described above, using SBP instead of DBP.

# Progression of spatial patterns of WMH

We performed an additional exploratory analysis to explore the spatial pattern of WMH progression in relation to CVR and cognition.   
Using the Bullseye approach, we divided the white matter into 36 parcels depending on their distance from the ventricles and the brain lobe (see Figure 5). We used FreeSurfer’s aparc+aseg segmentation of the longitudinally processed baseline acquisition. We determined the volume of WMH in each of these parcels for baseline and follow-up WMH segmentations obtained from LST by summing up all voxels with a WMH probability larger than 0.1. Five participants did not complete the FreeSurfer longitudinal pipeline and could therefore not be included in this analysis.  
Using parallel analysis implemented in the psych pacakge, we determined the optimal number of components and conducted principal component analysis with oblimin rotation on the baseline Bullseye WMH segmentation. We projected the data from the follow-up on these components and extracted four components score for baseline and follow-up.   
We replaced baseline and change in total WMH volume with baseline and change ni the component scores and used models M1 – M3 to assess the association of DBP/WHR and cognition with spatial WMH components.

#### 

# Results

## Flowchart

After applying exclusion criteria, the sample included 596 individuals with two timepoints (see Figure 1 for details on the exclusion and Table 6 for demographic characteristics at baseline).

## Confirmatory analyses

### H1: Baseline DBP and WMH progression

In model M1, we tested whether higher baseline DBP was associated with stronger WMH progression over time. There was no interaction of baseline DBP and time (one-sided corrected p-value = 0.41 and BF = 0.04 with moderate evidence against this hypothesis). The multivariate Wald test comparing a model with and without the interaction of baseline DBP and time, pooled across multiple imputations, yielded a p-value of 0.43. Table 7 shows two-sided uncorrected p-values for all CVR factors.  
Figure 2 shows the scatter plot and Bayes factor representations.

#### H2: WMH progression and executive function

In model M2, we investigated the association of higher WMH progression and executive function. There was no association of change in WMH volume with executive function (change in WMH volume: est(se) = -0.16(0.1), corrected one-sided p-value = 0.08 and BF = 0.99 (see Table 8)). The multivariate Wald test comparing a model with and without the change in WMH volume, pooled across multiple imputations, yielded a p-value of 0.13. Based on the BF between 0.3 and 3, these results are inconclusive.  
Figure 3 shows the scatter plots of the associations.

#### H3: WMH progression and global cognitive function

In model M3, we investigated the association of higher WMH progression and global cognition. Change in WMH volume was associated with stronger decline in global cognition (est(se) = -0.33(0.09), corrected one-sided p-value = 0.0002 and BF = 153.38). The multivariate Wald test comparing a model with and without the change in WMH volume, pooled across multiple imputations, yielded a p-value of 0.01. Table 9 shows uncorrected two-sided p-values and Figure 4 shows the scatter plots of the associations.

### Model Assumptions

Residuals and random effects were normally distributed for all models (see Supplementary Material). All VIF were below 10.  
There were 7, 27 and 20 unique influential cases across the five imputations for model M1, M2 and M3, respectively. Figures 5, 6 and 7 show original estimates, minimal and maximal estimates from random effect stability tests across imputations, robust LMM estimate and 95% CI and estimates and 95% CI from models without influential cases for each imputed dataset.

Estimates for the predictors of interest of models M1, M2 and M3 are depicted in figures 5, 6 and 7, respectively. Each figure shows original estimates with minimal and maximal estimates from random effect stability tests across imputations, robust LMM estimates with 95% CI across imputations and estimates with 95% CI from models without influential cases for each imputed dataset.

In M1, estimates for WHR change came with high uncertainty while all other estimates agreed well between the original model and models without influential cases, individual random effects and robust LMM.  
In Model M2, influential cases biased the estimates towards higher values for WML change. Robust estimates showed a similar trend.  
In Model M3, this bias for WML change was smaller. Still, the robust estimates were somewhat smaller than the original ones.

### Exploratory Analyses

#### E1a-E1c (DBP change, WHR baseline, WHR change)

We hypothesized that higher WHR at baseline and increases in WHR and DBP would be associated with a stronger increase of WMH volume over time.  
We used model 1 for exploring these associations. We found that higher increase in DBP was associated with stronger progression of WMH volume (est(se) = 0.006 (0.002), p-value = 0.0003 and BF = 110.71). There were no significant associations for WHR change or the interaction of age and WHR (see Table 6).

#### E2a - E3b: Interactions of gender, CVR risk, WMH progression and cognition

While men had significantly lower WMH volume at baseline (est(se) = -0.28 (0.09), p-value = 0.002), there was no significant interaction of gender and WMH progression, gender and DBP change on WMH progression or any interaction with DBP or WHR at baseline and WHR change.   
Men performed worse in executive function (est(se) = -0.24 (0.08), p-value = 0.002) and global cognitive function (est(se) = -0.3 (0.07), p-value = 0.00006) than women.  
There was no significant interaction of gender and change in WMH volume on executive function or global cognitive function change (see supplements and Tables 10, 11 and 12 for gender-stratified results).

### *E4: Association of SBP and WMH progression*

We also explored the association of SBP at baseline, change of SBP and WMH progression and found that baseline SBP predicted WMH progression (warum hier keine Effektgröße?, Wald p-value = 0.03, see Table 13). Similar to DBP change, SBP increase was also associated with WMH progression(würde dann hier auch die Effektgröße & Signifikanz hinzufügen).

### *E5: Spatial patterns of WMH progression*

We found that WMH progression was most pronounced in the frontal and parietal WM, especially in the deeper layers (see Figure 8).  
Parallel analysis indicated four to be the optimal number of components (shown in Figure 9). Component 1 included occipital periventricular WMH, component 2 was composed of WMH in deeper layers of the frontal, temporal and parietal lobes as well as the basal ganglia. Component 3 included frontal and basal ganglia periventricular WMH and component 4 mainly included deep occipital WMH.  
In Model M1, only component 3 was associated with an increase in DBP (est(sd) = 0.0045(0.0012), p-value = 0.00015). All components were cross-sectionally associated with age and only component 3 also increased over time while controlling for DBP (see Table 14).  
We found that only increases in C3 were significantly associated with increased decline in global cognitive function (est(sd)=-0.074(0.035), p=0.034) (see Table 15). None of the components was associated with decline in executive function.

# Discussion

In this registered report, we studied the progression of WMH with respect to risk factors and cognitive outcomes. We pre-registered three confirmatory hypotheses of which one was accepted. We found a significant association of WMH progression and global cognitive decline over 6 years. There was no significant effect of baseline DBP on WMH progression nor an association of WMH progression and executive functions decline, with Bayes Factors indicating evidence in favour of the null and inconclusive results, respectively.  
In exploratory analyses, we found that an increase in DBP was a significant predictor of WMH progression, independent of baseline DBP. WHR at baseline or change in WHR did not predict WMH progression. SBP at baseline and increase of SBP also predicted WMH progression. There was no significant interaction with gender for any of the effects. Overall, women had higher WMH volume than men but performed better in executive function and global cognitive function at baseline. WMH progression was mostly located in frontal periventricular regions, where also effects of blood pressure were most pronounced.

The mean annual WMH progression in this study was 0.17 cm3/y. This was comparable to the estimation in our power analysis (0.32 cm3/y) but lower than the figure reported by Brown, Low, and Markus ([2021](#ref-brown21)) (0.7 cm3/y) who also included stroke and dementia patients. Against our hypotheses, we did not find an interaction effect of baseline DBP with time since baseline on the progression of WMH. Previous studies mostly investigated annual change in WMH volume as outcome in a linear model, while we took the more flexible approach of using a mixed model. Both approaches should yield equivalent results (Walker ([2018](#ref-walker18))). In additional analyses, we found stronger effects of both baseline and change in DBP when using annual change in WMH volume as outcome in a linear model like in Debette et al. ([2011](#ref-debette11)) (both p<10⁻5). However, these models did not satisfy the assumptions of the linear model (non-normal distribution of residuals), possibly due to the zero-inflated and left-bounded distribution of WMH change (see supplementary Figures 1-3). When using change based on asinh-transformed WMH volumes at baseline and followup as outcome in a linear model, the association of baseline DBP with WMH change was reduced.  
In our confirmatory analysis, we found higher DBP increase related to increase in WMH volume, independent of baseline DBP. This was seen in both the preregistered mixed model analysis and in the change score models. Additionally, in an exploratory analyses, we found that both higher SBP at baseline and increase in SBP were associated with WMH progression in line with the literature.  
DBP reflects the balance between peripheral vascular resistance and large artery stiffness while SBP increases with both vascular resistance and large artery stiffness (Pinto ([2007](#ref-pinto07))). During aging, SBP and DBP increase in parallel, driven by both vascular resistance and large arterial stiffness until around 55 years. After that, large artery stiffness dominates and leads to further increases of SBP while DBP levels off or slightly decreases (Kaess et al. ([2012](#ref-kaess12)); Franklin et al. ([1997](#ref-franklin97))). Previous studies have stressed the stronger association of concurrent SBP with WMH volume in the elderly, and a stronger effect of mid-life DBP on WMH in late-life (Wartolowska and Webb ([2021](#ref-wartolowska21))). While this was a cross-sectional study, our results supported the stronger effect of baseline SBP compared to baseline DBP but similar effects of BP change (Wilkinson and Webb ([2022](#ref-wilkinson22))).  
Previous studies have focused on SBP reduction due to its strong age-related increase and greater importance for cardiovascular events in the elderly (Wang et al. ([2005](#ref-wang05))). In the SPRINT-MIND trial, the intensive SBP group (mean after intervention of 120 mm Hg) vs the standard SBP control group (mean of 135 mm Hg) showed significantly less WMH progression (0.92 cm3 vs 1.45 cm3) (Nasrallah et al. ([2019](#ref-nasrallahAssociationIntensiveVs2019))). DBP also reduced in the main SPRINT trial but no data was reported in relation to WMH progression (SPRINT Research Group et al. ([2015](#ref-sprintresearchgroup15))). Intensive BP control did not induce hypoperfusion in Croall et al. ([2018](#ref-croall18)) but excessively low DBP might be associated with an increased risk for stroke and cardiovascular disease (Somes et al. ([1999](#ref-somes99))).  
We did not find evidence for an association of abdominal obesity with WMH progression. Despite obesity being a risk factor for dementia, its association with imaging markers of cSVD is relatively small compared to hypertension (Arnoldussen et al. ([2019](#X7e74b322196fb7da72135ed9df16bfcb333c5a4)); Dearborn et al. ([2015](#ref-dearbornObesityInsulinResistance2015)); Livingston et al. ([2020](#X96507da29cdffbf85437bd6c75952483b9ef6d0)); Debette et al. ([2011](#ref-debette11))).   
In line with previous studies, we found that WMH progression was associated with global cognitive decline (Hamilton et al. ([2021](#ref-hamilton21)); Kloppenborg et al. ([2014](#X6c46b7734a36ad0b148dd2439f1429135d34f40))). This association amounted to a reduction of -0.03 in the normalized global cognition score per 1 cm3 of WMH volume increase (hier wäre vllt auch noch die Angabe pro SD hilfreich für Leser\_innen, die nicht super vertraut mit WMH sind) (while adjusting for age and time elapsed). A year elapsed accounted for -0.048 decrease in global cognition, or -0.044 when simultaneously adjusting for WMH change.  
We did not find statistically significant evidence of an association for executive function, yet the estimate was negative as expected and the BF of 0.99 indicated that no conclusive evidence could be drawn. Yet, the notion that WMH predominantly affect executive functions dependent on frontal brain networks was not supported by our data. Rather, our results are in line with a more universal negative effect of WMH volume on cognitive function (Hamilton et al. ([2021](#ref-hamilton21))).  
We did not find any gender-specific associations of risk factors or cognitive outcomes with WMH progression. While females had higher WMH volumes at baseline, progression was similar to previous studies (Lohner et al. ([2022](#ref-lohner22));Brown, Low, and Markus ([2021](#ref-brown21))). We did not find evidence for a differential association of cardiovascular risk factors and WMH progression between genders as suggested in (Alqarni et al. ([2020](#ref-alqarni20)); Sachdev et al. ([2009](#ref-sachdev09))). These studies, however, mostly investigated cross-sectional WMH volume and did not investigate the interaction of risk factors, gender and time. Also, regarding the cognitive consequences of WMH progression, no differences between genders were seen. Still, we cannot rule out that we were underpowered to detect these effects.  
Finally, in an exploratory analysis of spatial patterns of WMH, we found that WMH progression mainly occurred in the frontal periventricular WM. Progression was also observed in occipital periventricular WM but less so in deep occipital WM. This is in line with previous reports of gradual extension of existing WMH (which start to appear around the ventricles) into nearby normal appearing WM (Promjunyakul et al. ([2018](#Xf64b60b9208f140e6a87329cb3e70281ccfd3e8))). A stronger DBP increase was also associated with frontal-periventricular WMH expansion. There was no DBP or WHR-associated increase in any other spatial patterns. Specifically, component 4 including deep occipital WMH which might be reflective of cerebral amyloid angiopathy did not change in relation to the risk factors and was overall relatively stable (Thanprasertsuk et al. ([2014](#ref-thanprasertsuk14)); Charidimou et al. ([2022](#ref-charidimou22))). The lack of more specific associations might also reflect the relatively low total WMH volume and limited variability in the distribution of WMH in this cohort of community-dwelling elderly,   
Taken together, these results indicate that strict control of blood pressure in both men and women is recommended in order to limit WMH progression and related global cognitive decline.

# References

Alqarni, Abdullah, Jiyang Jiang, John D. Crawford, Forrest Koch, Henry Brodaty, Perminder Sachdev, and Wei Wen. 2020. “Sex Differences in Risk Factors for White Matter Hyperintensities in Non-demented Older Individuals.” *Neurobiology of Aging*. <https://doi.org/10.1016/j.neurobiolaging.2020.11.001>.

Armstrong, Nicola J., Karen A. Mather, Muralidharan Sargurupremraj, Maria J. Knol, Rainer Malik, Claudia L. Satizabal, Lisa R. Yanek, et al. 2020. “Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities.” *Stroke* 51 (7): 2111–21. <https://doi.org/10.1161/STROKEAHA.119.027544>.

Arnoldussen, Ilse A. C., Deborah R. Gustafson, Esther M. C. Leijsen, Frank-Erik de Leeuw, and Amanda J. Kiliaan. 2019. “Adiposity Is Related to Cerebrovascular and Brain Volumetry Outcomes in the RUN DMC Study.” *Neurology* 93 (9): e864. <https://doi.org/10.1212/WNL.0000000000008002>.

Beyer, F., S. Kharabian Masouleh, J. M. Huntenburg, L. Lampe, T. Luck, S. G. Riedel-Heller, M. Loeffler, et al. 2017. “Higher Body Mass Index Is Associated with Reduced Posterior Default Mode Connectivity in Older Adults.” *Hum Brain Mapp* 38 (7): 3502–15. <https://doi.org/10.1002/hbm.23605>.

Bos, Daniel, Frank J. Wolters, Sirwan K. L. Darweesh, Meike W. Vernooij, Frank de Wolf, M. Arfan Ikram, and Albert Hofman. 2018. “Cerebral Small Vessel Disease and the Risk of Dementia: A Systematic Review and Meta-Analysis of Population-Based Evidence.” *Alzheimer’s & Dementia* 14 (11): 1482–92. <https://doi.org/10.1016/j.jalz.2018.04.007>.

Brown, Robin, Audrey Low, and Hugh S. Markus. 2021. “Rate of, and Risk Factors for, White Matter Hyperintensity Growth: A Systematic Review and Meta-Analysis with Implications for Clinical Trial Design.” *Journal of Neurology, Neurosurgery & Psychiatry* 92 (12): 1271–77. <https://doi.org/10.1136/jnnp-2021-326569>.

Brugulat-Serrat, Anna, Gemma Salvadó, Carole H. Sudre, Oriol Grau-Rivera, Marc Suárez-Calvet, Carles Falcon, Gonzalo Sánchez-Benavides, et al. 2020. “Patterns of White Matter Hyperintensities Associated with Cognition in Middle-Aged Cognitively Healthy Individuals.” *Brain Imaging and Behavior* 14 (5): 2012–23. <https://doi.org/10.1007/s11682-019-00151-2>.

Charidimou, Andreas, Gregoire Boulouis, Matthew P. Frosch, Jean-Claude Baron, Marco Pasi, Jean Francois Albucher, Gargi Banerjee, et al. 2022. “The Boston Criteria Version 2.0 for Cerebral Amyloid Angiopathy: A Multicentre, Retrospective, MRI-neuropathology Diagnostic Accuracy Study.” *The Lancet. Neurology* 21 (8): 714–25. <https://doi.org/10.1016/S1474-4422(22)00208-3>.

Croall, Iain D., Daniel J. Tozer, Barry Moynihan, Usman Khan, John T. O’Brien, Robin G. Morris, Victoria C. Cambridge, et al. 2018. “Effect of Standard Vs Intensive Blood Pressure Control on Cerebral Blood Flow in Small Vessel Disease: The PRESERVE Randomized Clinical Trial.” *JAMA Neurology* 75 (6): 720–27. <https://doi.org/10.1001/jamaneurol.2017.5153>.

d’Arbeloff, Tracy, Maxwell L. Elliott, Annchen R. Knodt, Tracy R. Melzer, Ross Keenan, David Ireland, Sandhya Ramrakha, et al. 2019. “White Matter Hyperintensities Are Common in Midlife and Already Associated with Cognitive Decline.” *Brain Commun* 1 (1). <https://doi.org/10.1093/braincomms/fcz041>.

de Havenon, Adam, Jennifer J. Majersik, David L. Tirschwell, J. Scott McNally, Gregory Stoddard, and Natalia S. Rost. 2019. “Blood Pressure, Glycemic Control, and White Matter Hyperintensity Progression in Type 2 Diabetics.” *Neurology* 92 (11): e1168–75.

De Leeuw, F. E., Jan Cees de Groot, E. Achten, Matthijs Oudkerk, L. M. P. Ramos, R. Heijboer, A. Hofman, J. Jolles, J. Van Gijn, and M. M. B. Breteler. 2001. “Prevalence of Cerebral White Matter Lesions in Elderly People: A Population Based Magnetic Resonance Imaging Study. The Rotterdam Scan Study.” *Journal of Neurology, Neurosurgery & Psychiatry* 70 (1): 9–14.

Dearborn, Jennifer L., Andrea L. C. Schneider, A. Richey Sharrett, Thomas H. Mosley, Daniel C. Bezerra, David S. Knopman, Elizabeth Selvin, Clifford R. Jack, Laura H. Coker, and Alvaro Alonso. 2015. “Obesity, Insulin Resistance, and Incident Small Vessel Disease on Magnetic Resonance Imaging: Atherosclerosis Risk in Communities Study.” *Stroke* 46 (11): 3131–36.

Debette, S., S. Seshadri, A. Beiser, R. Au, J. J. Himali, C. Palumbo, P. A. Wolf, and C. DeCarli. 2011. “Midlife Vascular Risk Factor Exposure Accelerates Structural Brain Aging and Cognitive Decline.” *Neurology* 77 (5): 461–68. <https://doi.org/10.1212/WNL.0b013e318227b227>.

Debette, Stéphanie, Sabrina Schilling, Marie-Gabrielle Duperron, Susanna C. Larsson, and Hugh S. Markus. 2019. “Clinical Significance of Magnetic Resonance Imaging Markers of Vascular Brain Injury: A Systematic Review and Meta-analysis.” *JAMA Neurology* 76 (1): 81–94. <https://doi.org/10.1001/jamaneurol.2018.3122>.

Dickie, David Alexander, Sherif Karama, Stuart J. Ritchie, Simon R. Cox, Eleni Sakka, Natalie A. Royle, Benjamin S. Aribisala, Maria Valdés Hernández, Susana Muñoz Maniega, and Alison Pattie. 2016. “Progression of White Matter Disease and Cortical Thinning Are Not Related in Older Community-Dwelling Subjects.” *Stroke* 47 (2): 410–16.

Duering, Marco, Geert Jan Biessels, Amy Brodtmann, Christopher Chen, Charlotte Cordonnier, Frank-Erik de Leeuw, Stéphanie Debette, et al. 2023. “Neuroimaging Standards for Research into Small Vessel Diseaseadvances Since 2013.” *The Lancet Neurology* 22 (7): 602–18. <https://doi.org/10.1016/S1474-4422(23)00131-X>.

Dufouil, C., A. de KersaintGilly, V. Besancon, C. Levy, E. Auffray, L. Brunnereau, A. Alperovitch, and C. Tzourio. 2001. “Longitudinal Study of Blood Pressure and White Matter Hyperintensities: The EVA MRI Cohort.” *Neurology* 56 (7): 921–26.

Dufouil, C., S. Seshadri, and G. Chene. 2014. “Cardiovascular Risk Profile in Women and Dementia.” *J Alzheimers Dis* 42 Suppl 4 (1875-8908 (Electronic)): S353–63. <https://doi.org/10.3233/JAD-141629>.

Engel, Christoph, Kerstin Wirkner, Samira Zeynalova, Ronny Baber, Hans Binder, Uta Ceglarek, Cornelia Enzenbach, et al. 2022. “Cohort Profile: The LIFE-Adult-Study.” *International Journal of Epidemiology*, dyac114. <https://doi.org/10.1093/ije/dyac114>.

Fatemi, Farzan, Kejal Kantarci, Jonathan Graff-Radford, Gregory M. Preboske, Stephen D. Weigand, Scott A. Przybelski, David S. Knopman, et al. 2018. “Sex Differences in Cerebrovascular Pathologies on FLAIR in Cognitively Unimpaired Elderly.” *Neurology* 90 (6): e466. <https://doi.org/10.1212/WNL.0000000000004913>.

Franklin, Stanley S., William Gustin, Nathan D. Wong, Martin G. Larson, Michael A. Weber, William B. Kannel, and Daniel Levy. 1997. “Hemodynamic Patterns of Age-Related Changes in Blood Pressure.” *Circulation* 96 (1): 308–15. <https://doi.org/10.1161/01.CIR.96.1.308>.

Godin, Ophélia, Christophe Tzourio, Pauline Maillard, Bernard Mazoyer, and Carole Dufouil. 2011. “Antihypertensive Treatment and Change in Blood Pressure Are Associated with the Progression of White Matter Lesion Volumes: The Three-City (3C)Dijon Magnetic Resonance Imaging Study.” *Circulation* 123 (3): 266–73.

Gottesman Rebecca, F., Josef Coresh, J. Catellier Diane, A. Richey Sharrett, M. Rose Kathryn, H. Coker Laura, K. Shibata Dean, S. Knopman David, R. Jack Clifford, and H. Mosley Thomas. 2010. “Blood Pressure and White-Matter Disease Progression in a Biethnic Cohort.” *Stroke* 41 (1): 3–8. <https://doi.org/10.1161/STROKEAHA.109.566992>.

Griffanti, Ludovica, Mark Jenkinson, Sana Suri, Enikő Zsoldos, Abda Mahmood, Nicola Filippini, Claire E. Sexton, et al. 2018. “Classification and Characterization of Periventricular and Deep White Matter Hyperintensities on MRI: A Study in Older Adults.” *NeuroImage* 170: 174–81. <https://doi.org/10.1016/j.neuroimage.2017.03.024>.

Gustafson, D., L. Lissner, C. Bengtsson, C. Bjorkelund, and I. Skoog. 2004. “A 24-Year Follow-up of Body Mass Index and Cerebral Atrophy.” *Neurology* 63 (10): 1876–81.

Hajek, André, and Hans-Helmut König. 2020. “Fear of Dementia in the General Population: Findings from the German Socio-Economic Panel (GSOEP).” *Journal of Alzheimer’s Disease* 75: 1135–40. <https://doi.org/10.3233/JAD-200106>.

Hamilton, O., S. R. Cox, J. A. Okely, F. Conte, L. Ballerini, M. E. Bastin, J. Corley, et al. 2021. “Cerebral Small Vessel Disease Burden and Longitudinal Cognitive Decline from Age 73 to 82: The Lothian Birth Cohort 1936.” *Translational Psychiatry* 11 (1): 1–12. <https://doi.org/10.1038/s41398-021-01495-4>.

Hamilton, Olivia K. L., Ellen V. Backhouse, Esther Janssen, Angela C. C. Jochems, Caragh Maher, Tuula E. Ritakari, Anna J. Stevenson, Lihua Xia, Ian J. Deary, and Joanna M. Wardlaw. 2021. “Cognitive Impairment in Sporadic Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis.” *Alzheimer’s & Dementia* 17 (4): 665–85.

Heidari, Shirin, Thomas F. Babor, Paola De Castro, Sera Tort, and Mirjam Curno. 2016. “Sex and Gender Equity in Research: Rationale for the SAGER Guidelines and Recommended Use.” *Research Integrity and Peer Review* 1 (1): 1–9.

Higuchi, Satoshi, Yusuke Kabeya, and Kiyoe Kato. 2017. “Visceral-to-Subcutaneous Fat Ratio Is Independently Related to Small and Large Cerebrovascular Lesions Even in Healthy Subjects.” *Atherosclerosis* 259: 41–45. <https://doi.org/10.1016/j.atherosclerosis.2017.03.001>.

Jansen, Michelle G, Ludovica Griffanti, Clare E Mackay, Melis Anatürk, Luca Melazzini, Ann-Marie G de Lange, Nicola Filippini, et al. 2022. “Association of Cerebral Small Vessel Disease Burden with Brain Structure and Cognitive and Vascular Risk Trajectories in Mid-to-Late Life.” *Journal of Cerebral Blood Flow & Metabolism* 42 (4): 600–612. <https://doi.org/10.1177/0271678X211048411>.

Jiménez-Balado, Joan, Fabian Corlier, Christian Habeck, Yaakov Stern, and Teal Eich. 2022. “Effects of White Matter Hyperintensities Distribution and Clustering on Late-Life Cognitive Impairment.” *Scientific Reports* 12 (1): 1955.

Jiménez-Sánchez, Lorena, Olivia K. L. Hamilton, Una Clancy, Ellen V. Backhouse, Catriona R. Stewart, Michael S. Stringer, Fergus N. Doubal, and Joanna M. Wardlaw. 2021. “Sex Differences in Cerebral Small Vessel Disease: A Systematic Review and Meta-Analysis.” *Frontiers in Neurology* 12.

Jorgensen, Dana R., C. Elizabeth Shaaban, Clayton A. Wiley, Peter J. Gianaros, Joseph Mettenburg, and Caterina Rosano. 2018. “A Population Neuroscience Approach to the Study of Cerebral Small Vessel Disease in Midlife and Late Life: An Invited Review.” *American Journal of Physiology-Heart and Circulatory Physiology* 314 (6): H1117–36.

Kaess, Bernhard M., Jian Rong, Martin G. Larson, Naomi M. Hamburg, Joseph A. Vita, Daniel Levy, Emelia J. Benjamin, Ramachandran S. Vasan, and Gary F. Mitchell. 2012. “Aortic Stiffness, Blood Pressure Progression, and Incident Hypertension.” *JAMA* 308 (9): 875–81. <https://doi.org/10.1001/2012.jama.10503>.

Kharabian Masouleh, S., K. Arelin, A. Horstmann, L. Lampe, J. A. Kipping, T. Luck, S. G. Riedel-Heller, et al. 2016. “Higher Body Mass Index in Older Adults Is Associated with Lower Gray Matter Volume: Implications for Memory Performance.” *Neurobiol Aging* 40 (April): 1–10. <https://doi.org/10.1016/j.neurobiolaging.2015.12.020>.

Kim, K. W., H. Seo, M. S. Kwak, and D. Kim. 2017. “Visceral Obesity Is Associated with White Matter Hyperintensity and Lacunar Infarct.” *International Journal of Obesity* 41 (5): 683–88. <https://doi.org/10.1038/ijo.2017.13>.

Kloppenborg, Raoul P., Paul J. Nederkoorn, Mirjam I. Geerlings, and Esther van den Berg. 2014. “Presence and Progression of White Matter Hyperintensities and Cognition.” *Neurology* 82 (23): 2127. <https://doi.org/10.1212/WNL.0000000000000505>.

Kynast, Jana, Leonie Lampe, Tobias Luck, Stefan Frisch, Katrin Arelin, Karl-Titus Hoffmann, Markus Loeffler, Steffi G. Riedel-Heller, Arno Villringer, and Matthias L. Schroeter. 2018. “White Matter Hyperintensities Associated with Small Vessel Disease Impair Social Cognition Beside Attention and Memory.” *Journal of Cerebral Blood Flow & Metabolism* 38 (6): 996–1009.

Lampe, Leonie, Shahrzad Kharabian-Masouleh, Jana Kynast, Katrin Arelin, Christopher J. Steele, Markus Löffler, A. Veronica Witte, Matthias L. Schroeter, Arno Villringer, and Pierre-Louis Bazin. 2019. “Lesion Location Matters: The Relationships Between White Matter Hyperintensities on Cognition in the Healthy Elderly.” *Journal of Cerebral Blood Flow & Metabolism* 39 (1): 36–43. <https://doi.org/10.1177/0271678X17740501>.

Lampe, Leonie, Rui Zhang, Frauke Beyer, Sebastian Huhn, Shahrzad Kharabian Masouleh, Sven Preusser, Pierre-Louis Bazin, Matthias L. Schroeter, Arno Villringer, and A. Veronica Witte. 2019. “Visceral Obesity Relates to Deep White Matter Hyperintensities via Inflammation.” *Annals of Neurology* 85 (2): 194–203. <https://doi.org/10.1002/ana.25396>.

Lampert, Thomas, L. Kroll, Stephan Müters, and Heribert Stolzenberg. 2013. “Messung Des Sozioökonomischen Status in Der Studie Zur Gesundheit Erwachsener in Deutschland (DEGS1).” *Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz* 56 (5-6): 631–36.

Livingston, Gill, Jonathan Huntley, Andrew Sommerlad, David Ames, Clive Ballard, Sube Banerjee, Carol Brayne, et al. 2020. “Dementia Prevention, Intervention, and Care: 2020 Report of the Lancet Commission.” *The Lancet* 396 (10248): 413–46. <https://doi.org/10.1016/s0140-6736(20)30367-6>.

Loeffler, M., C. Engel, P. Ahnert, D. Alfermann, K. Arelin, R. Baber, F. Beutner, et al. 2015. “The LIFE-Adult-Study: Objectives and Design of a Population-Based Cohort Study with 10,000 Deeply Phenotyped Adults in Germany.” *BMC Public Health* 15 (1): 691. <https://doi.org/10.1186/s12889-015-1983-z>.

Lohner, Valerie, Gökhan Pehlivan, Gerard Sanroma, Anne Miloschewski, Markus D. Schirmer, Tony Stöcker, Martin Reuter, and Monique M. B. Breteler. 2022. “Relation Between Sex, Menopause, and White Matter Hyperintensities: The Rhineland Study.” *Neurology* 99 (9): e935–43. <https://doi.org/10.1212/WNL.0000000000200782>.

Marini, Sandro, D. Anderson Christopher, and Jonathan Rosand. 2020. “Genetics of Cerebral Small Vessel Disease.” *Stroke* 51 (1): 12–20. <https://doi.org/10.1161/STROKEAHA.119.024151>.

Morris, J. C., A. Heyman, R. C. Mohs, J. P. Hughes, G. Van Belle, GDME Fillenbaum, E. D. Mellits, and C. Clark. 1989. “The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): I. Clinical and Neuropsychological Assessment of Alzheimer’s Disease.” *Neurology*.

Morys, Filip, Mahsa Dadar, and Alain Dagher. 2021. “Association Between Mid-Life Obesity, Its Metabolic Consequences, Cerebrovascular Disease and Cognitive Decline.” *The Journal of Clinical Endocrinology & Metabolism*.

Nasrallah, I. M., N. M. Pajewski, A. P. Auchus, G. Chelune, A. K. Cheung, M. L. Cleveland, L. H. Coker, et al. 2019. “Association of Intensive Vs Standard Blood Pressure Control With Cerebral White Matter Lesions.” *JAMA* 322 (6): 524–34. <https://doi.org/10.1001/jama.2019.10551>.

Nowok, Beata, Gillian M. Raab, and Chris Dibben. 2016. “Synthpop: Bespoke Creation of Synthetic Data in R.” *J Stat Softw* 74 (11): 1–26.

Oosterman, Joukje M., Raymond L. C. Vogels, Barbera van Harten, Alida A. Gouw, Anna Poggesi, Philip Scheltens, Roy P. C. Kessels, and Erik J. A. Scherder. 2010. “Assessing Mental Flexibility: Neuroanatomical and Neuropsychological Correlates of the Trail Making Test in Elderly People.” *The Clinical Neuropsychologist* 24 (2): 203–19. <https://doi.org/10.1080/13854040903482848>.

Peng, Jie, Fanghong Lu, Zhihao Wang, Ming Zhong, Lixin Sun, Na Hu, Zhendong Liu, and Wei Zhang. 2014. “Excessive Lowering of Blood Pressure Is Not Beneficial for Progression of Brain White Matter Hyperintensive and Cognitive Impairment in Elderly Hypertensive Patients: 4-Year Follow-Up Study.” *Journal of the American Medical Directors Association* 15 (12): 904–10. <https://doi.org/10.1016/j.jamda.2014.07.005>.

Pinto, Elisabete. 2007. “Blood Pressure and Ageing.” *Postgraduate Medical Journal* 83 (976): 109–14. <https://doi.org/10.1136/pgmj.2006.048371>.

Promjunyakul, Nutta-on, Hiroko H. Dodge, David Lahna, Erin L. Boespflug, Jeffrey A. Kaye, William D. Rooney, and Lisa C. Silbert. 2018. “Baseline NAWM Structural Integrity and CBF Predict Periventricular WMH Expansion over Time.” *Neurology* 90 (24): e2119. <https://doi.org/10.1212/WNL.0000000000005684>.

Reuter, Martin, Nicholas J. Schmansky, H. Diana Rosas, and Bruce Fischl. 2012. “Within-Subject Template Estimation for Unbiased Longitudinal Image Analysis.” *NeuroImage* 61 (4): 1402–18. <https://doi.org/10.1016/j.neuroimage.2012.02.084>.

Sachdev, P. S., R. Parslow, W. Wen, K. J. Anstey, and S. Easteal. 2009. “Sex Differences in the Causes and Consequences of White Matter Hyperintensities.” *Neurobiology of Aging* 30 (6): 946–56. <https://doi.org/10.1016/j.neurobiolaging.2007.08.023>.

Sachdev, Perminder, Wei Wen, Xiaohua Chen, and Henry Brodaty. 2007. “Progression of White Matter Hyperintensities in Elderly Individuals over 3 Years.” *Neurology* 68 (3): 214–22.

Scharf, E. L., J. Graff-Radford, S. A. Przybelski, T. G. Lesnick, M. M. Mielke, D. S. Knopman, G. M. Preboske, et al. 2019. “Cardiometabolic Health and Longitudinal Progression of White Matter Hyperintensity: The Mayo Clinic Study of Aging.” *Stroke* 50 (11): 3037–44. <https://doi.org/10.1161/STROKEAHA.119.025822>.

Schmidt, Paul, Viola Pongratz, Pascal Küster, Dominik Meier, Jens Wuerfel, Carsten Lukas, Barbara Bellenberg, et al. 2019. “Automated Segmentation of Changes in FLAIR-hyperintense White Matter Lesions in Multiple Sclerosis on Serial Magnetic Resonance Imaging.” *NeuroImage: Clinical* 23: 101849. <https://doi.org/10.1016/j.nicl.2019.101849>.

Schmidt, Paul, and Lucie Wink. 2017. “LST: A Lesion Segmentation Tool for SPM.” *Manual/Documentation for Version* 2: 15.

Schmidt, Reinhold, Stefan Ropele, Christian Enzinger, Katja Petrovic, Stephen Smith, Helena Schmidt, Paul M. Matthews, and Franz Fazekas. 2005. “White Matter Lesion Progression, Brain Atrophy, and Cognitive Decline: The Austrian Stroke Prevention Study.” *Annals of Neurology* 58 (4): 610–16. <https://doi.org/10.1002/ana.20630>.

Somes, Grant W., Marco Pahor, Ronald I. Shorr, William C. Cushman, and William B. Applegate. 1999. “The Role of Diastolic Blood Pressure When Treating Isolated Systolic Hypertension.” *Archives of Internal Medicine* 159 (17): 2004–9. <https://doi.org/10.1001/archinte.159.17.2004>.

SPRINT Research Group, Jackson T. Wright, Jeff D. Williamson, Paul K. Whelton, Joni K. Snyder, Kaycee M. Sink, Michael V. Rocco, et al. 2015. “A Randomized Trial of Intensive Versus Standard Blood-Pressure Control.” *The New England Journal of Medicine* 373 (22): 2103–16. <https://doi.org/10.1056/NEJMoa1511939>.

Sudre, C. H., B. Gomez Anson, I. Davagnanam, A. Schmitt, A. F. Mendelson, F. Prados, Lorna Smith, D. Atkinson, A. D. Hughes, and N. Chaturvedi. 2018. “Bullseye’s Representation of Cerebral White Matter Hyperintensities.” *Journal of Neuroradiology* 45 (2): 114–22.

Thanprasertsuk, Sekh, Sergi Martinez-Ramirez, Octavio Marques Pontes-Neto, Jun Ni, Alison Ayres, Anne Reed, Kyleen Swords, M. Edip Gurol, Steven M. Greenberg, and Anand Viswanathan. 2014. “Posterior White Matter Disease Distribution as a Predictor of Amyloid Angiopathy.” *Neurology* 83 (9): 794–800. <https://doi.org/10.1212/WNL.0000000000000732>.

Veldsman, Michele, Petya Kindalova, Masud Husain, Ioannis Kosmidis, and Thomas E. Nichols. 2020. “Spatial Distribution and Cognitive Impact of Cerebrovascular Risk-Related White Matter Hyperintensities.” *NeuroImage: Clinical* 28 (January): 102405. <https://doi.org/10.1016/j.nicl.2020.102405>.

Verhaaren, Benjamin F. J., Stéphanie Debette, Joshua C. Bis, Jennifer A. Smith, M. Kamran Ikram, Hieab H. Adams, Ashley H. Beecham, Kumar B. Rajan, Lorna M. Lopez, and Sandra Barral. 2015. “Multiethnic Genome-Wide Association Study of Cerebral White Matter Hyperintensities on MRI.” *Circulation: Cardiovascular Genetics* 8 (2): 398–409.

Vermeer, Sarah E., William T. Longstreth, and Peter J. Koudstaal. 2007. “Silent Brain Infarcts: A Systematic Review.” *The Lancet Neurology* 6 (7): 611–19. <https://doi.org/10.1016/S1474-4422(07)70170-9>.

Vuorinen, M., A. Solomon, S. Rovio, L. Nieminen, I. Kåreholt, J. Tuomilehto, H. Soininen, and M. Kivipelto. 2011. “Changes in Vascular Risk Factors from Midlife to Late Life and White Matter Lesions: A 20-Year Follow-Up Study.” *Dementia and Geriatric Cognitive Disorders* 31 (2): 119–25. <https://doi.org/10.1159/000323810>.

Walker, Jeffrey A. 2018. *Applied Statistics for Experimental Biology*.

Wang, Ji-Guang, Jan A. Staessen, Stanley S. Franklin, Robert Fagard, and François Gueyffier. 2005. “Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular Outcome.” *Hypertension* 45 (5): 907–13. <https://doi.org/10.1161/01.HYP.0000165020.14745.79>.

Wardlaw, Joanna M., Colin Smith, and Martin Dichgans. 2019. “Small Vessel Disease: Mechanisms and Clinical Implications.” *The Lancet Neurology* 18 (7): 684–96. <https://doi.org/10.1016/S1474-4422(19)30079-1>.

Wartolowska, Karolina Agnieszka, and Alastair John Stewart Webb. 2021. “Midlife Blood Pressure Is Associated with the Severity of White Matter Hyperintensities: Analysis of the UK Biobank Cohort Study.” *European Heart Journal* 42 (7): 750–57. <https://doi.org/10.1093/eurheartj/ehaa756>.

Wen, Wei, Perminder S. Sachdev, Jason J. Li, Xiaohua Chen, and Kaarin J. Anstey. 2009. “White Matter Hyperintensities in the Forties: Their Prevalence and Topography in an Epidemiological Sample Aged 4448.” *Human Brain Mapping* 30 (4): 1155–67. <https://doi.org/10.1002/hbm.20586>.

Wilkinson, Imogen, and Alastair John Stewart Webb. 2022. “Consistency of Associations of Systolic and Diastolic Blood Pressure with White Matter Hyperintensities: A Meta-Analysis.” *International Journal of Stroke* 17 (3): 291–98. <https://doi.org/10.1177/17474930211043364>.

Williamson, Wilby, Adam J. Lewandowski, Nils D. Forkert, Ludovica Griffanti, Thomas W. Okell, Jill Betts, Henry Boardman, Timo Siepmann, David McKean, and Odaro Huckstep. 2018. “Association of Cardiovascular Risk Factors with MRI Indices of Cerebrovascular Structure and Function and White Matter Hyperintensities in Young Adults.” *Jama* 320 (7): 665–73.

Yamashiro, K., R. Tanaka, Y. Tanaka, N. Miyamoto, Y. Shimada, Y. Ueno, T. Urabe, and N. Hattori. 2014. “Visceral Fat Accumulation Is Associated with Cerebral Small Vessel Disease.” *European Journal of Neurology* 21 (4): 667–73. <https://doi.org/10.1111/ene.12374>.

Zhang, D., Y. Tang, J. Ge, Y. Liu, J. Jin, and M. He. 2020. “Age and Diastolic Blood Pressure Play an Important Role in the Progression of White Matter Lesions: A Meta-Analysis.” *European Neurology* 83 (4): 351–59. <https://doi.org/10.1159/000510077>.

Zhang, Hua, Yi Cui, Yingxin Zhao, Yuanli Dong, Dandan Duan, Juan Wang, Lin Sheng, Tiantian Ji, Tingting Zhou, and Wenjing Hu. 2019. “Effects of Sartans and Low-Dose Statins on Cerebral White Matter Hyperintensities and Cognitive Function in Older Patients with Hypertension: A Randomized, Double-Blind and Placebo-Controlled Clinical Trial.” *Hypertension Research* 42 (5): 717–29.

**Tables**

***Table 1:*** *Cross-sectional estimates of Age, SBP, WHR, Gender and ICV on WMH load*

|  |  |  |
| --- | --- | --- |
| N=1574 | Estimate | Standard Error |
| Intercept | 1.44 | 0.09 |
| Age | 0.067 | 0.007 |
| SBP | 0.011 | 0.003 |
| WHR | 2.15 | 0.74 |
| Gender (male) | -0.40 | 0.15 |
| ICV | 0.000002 | 0.0000007 |

***Table 2:*** *Publications used for the effect of time on WML volume*

|  |  |  |  |
| --- | --- | --- | --- |
| Publication | Type of study, number of participants | Time between time points | Effect size of time on WML volume Mean(sd) of annual increase or point estimates |
| (Scharf et al., 2019) | Epidemiological study  N=554 | 3 years | 60-69y: 0.54 (1.27) cm³/y n=247 70-79y: 1.04 (1.93) cm³/y n=186 80+: 1.6 (2.4) cm³/y n=121 |
| (Dickie et al., 2016) | Cohort study  N=439 | 3 years | 11.9 ± 11.7 cm³ at 73 years 15.9±14.6 cm³ at 76 years |
| (Godin et al., 2011) | Epidemiological study  N=1319 | 4 years | 1.07(2.76) cm³ over 4 years |
| (Peng et al., 2014) | Epidemiological study of hypertensive patients N=294 | 4 years | Baseline: 13.78 cm³+-6.67  Followup: 17.82 cm³ +-8.74 |
| (Schmidt et al., 2005) | Epidemiological study  N=243 | 6 years | 1.38(3.76 ml) cm³ |
| (Maillard et al.) | Epidemiological study  N=1118 | 4 years | 0.25 (0.56) cm³/year |
| (Nasrallah et al., 2019) | Intervention study, hypertensive patients from standard treatment group  N=200 | 3.98 years | 1.45 cm³ |
| (de Havenon et al., 2019), | Intervention study, diabetic patients in the glycemic intervention arm  N=502 | 40 months | 0.93 ± 1.20 cm³ |

***Table 3:*** *Studies used to estimate the longitudinal effects of baseline SBP and change in SBP on WML progression*

|  |  |  |  |
| --- | --- | --- | --- |
| Publication | Type of study, number of participants | Time between time points | Effect size of baseline SBP on WML progression |
| (Godin et al., 2011) | Epidemiological study  N=1319 | 4 years | 0.04 (0.02) cm³ per 5mmHg |
| (Dickie et al., 2016) | Cohort study  N=439 | 3 years | 0.0271 cm³ |
| (Gottesman Rebecca et al., 2010) | Epidemiological study  N=983 | 6 years | 1.1 cm³ in 10 years /20 mmHg |
| (Verhaaren et al., 2013) | Epidemiological study  N=1118 | ~4 years | 0.08 (0.03; 0.14) cm³/y per SD of SBP SD = 18 mmHg |
| Publication | Type of study, number of participants | Time between time points | Effect size of change in SBP on WML load |
| (Godin et al., 2011) | Epidemiological study  N=1319 | 4 years | 0.05 (0.02) cm³ per 5mmHG SBP increase |

***Table 4:*** *Simulated power (α < 0.05, one-sided tests) to detect an interaction effect of baseline SBP and WHR with age change and effects of change in SBP and WHR on progression of WMH.*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Sample size | Interaction of SBP baseline with age change | Interaction of WHR baseline with age change | SBP change | WHR change | WHR factor |
| 400 | 0.62 | 0 | 0 | 0 | 0.5 |
| 600 | 0.9 | 0 | 0.02 | 0 | 0.5 |
| 800 | 0.98 | 0 | 0 | 0 | 0.5 |
| 1000 | 1 | 0 | 0.02 | 0 | 0.5 |
| 400 | 0.78 | 0 | 0.04 | 0.02 | 1 |
| 600 | 0.96 | 0 | 0.02 | 0.02 | 1 |
| 800 | 0.98 | 0 | 0.02 | 0 | 1 |
| 1000 | 0.98 | 0 | 0.04 | 0.04 | 1 |
| 400 | 0.84 | 0 | 0.02 | 0 | 1.5 |
| 600 | 0.86 | 0.1 | 0.04 | 0.02 | 1.5 |
| 800 | 1 | 0.16 | 0.06 | 0 | 1.5 |
| 1000 | 1 | 0.12 | 0.04 | 0 | 1.5 |

***Table 5:*** *Simulated average one-sided Bayes Factors for the interaction effect of baseline DBP and baseline WHR with age change and SBP and WHR change on progression of WMH*.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Sample size | Interaction of DBP baseline with age change | Interaction of WHR baseline with age change | DBP change | WHR change | WHR factor |
| 400 | 1.15 | 0 | 0 | 0 | 0.5 |
| 600 | 3.68 | 0 | 0 | 0 | 0.5 |
| 800 | 18 | 0 | 0.05 | 0 | 0.5 |
| 1000 | 40.3 | 0 | 0.05 | 0 | 0.5 |
| 400 | 1.10 | 0 | 0 | 0 | 1 |
| 600 | 4.26 | 0 | 0 | 0 | 1 |
| 800 | 8.80 | 0 | 0.06 | 0 | 1 |
| 1000 | 8.33 | 0 | 0 | 0 | 1 |
| 400 | 2.26 | 0.09 | 0 | 0 | 1.5 |
| 600 | 1.94 | 0 | 0 | 0 | 1.5 |
| 800 | 39.4 | 0.09 | 0 | 0 | 1.5 |
| 1000 | 78.4 | 0 | 0 | 0 | 1.5 |

**Table 6:** Baseline demographic characteristics of participants included in the study

|  | N (%) | Mean | SD |
| --- | --- | --- | --- |
| Age (y) | 596 | 63.2 | 8.94 |
| Females | 263 (44.1%) |  |  |
| Tertiary Education | 313 (52.8%) |  |  |
| DBP (mmHg) | 590 | 76.3 | 9.33 |
| WHR | 595 | 0.941 | 0.0855 |
| CESD | 554 | 2.64 | 0.8 |
| Antihypertensive Medication | 261 (43.9%) |  |  |
| WMH volume (cm³) | 596 | 1.88 | 3.87 |

**Table 7:** Results of Model M1 testing the association of baseline DBP with WMH progression

|  | Estimate [95 % CI] | p-value |
| --- | --- | --- |
| Age at baseline | 0.056 [0.049, 0.062] | <0.001 |
| Time | 0.026 [-0.030, 0.083] | 0.360 |
| Baseline DBP | 0.012 [0.005, 0.018] | <0.001 |
| DBP change | 0.006 [0.003, 0.009] | <0.001 |
| Baseline WHR | 0.843 [-0.117, 1.802] | 0.085 |
| WHR change | -0.084 [-0.682, 0.515] | 0.784 |
| DBP x Time | 0.000 [-0.001, 0.000] | 0.612 |
| WHR x Time | 0.029 [-0.017, 0.076] | 0.218 |

**Table 8:** Association of WMH progression and executive function

|  | Estimate [95 % CI] | p-value |
| --- | --- | --- |
| Age at baseline | -0.017 [-0.026, -0.008] | <0.001 |
| Time | -0.047 [-0.061, -0.033] | <0.001 |
| Baseline WMH volume | -0.017 [-0.116, 0.082] | 0.740 |
| Change in WMH volume | -0.159 [-0.360, 0.041] | 0.120 |

**Table 9:** Association of WMH progression and global cognitive function

|  | Estimate [95 % CI] | p-value |
| --- | --- | --- |
| Age at baseline | -0.045 [-0.053, -0.037] | <0.001 |
| Time | -0.040 [-0.052, -0.028] | <0.001 |
| Baseline WMH volume | -0.044 [-0.135, 0.047] | 0.344 |
| Change in WMH volume | -0.326 [-0.497, -0.154] | <0.001 |

**Table 10:** Gender-stratified results for Model M1 on CVR factors

|  | Females: Estimate  [95 % CI] | Females: p-value | Males: Estimate  [95 % CI] | Males: p-value |
| --- | --- | --- | --- | --- |
| Age at baseline | 0.058 [0.046, 0.069] | <0.001 | 0.054 [0.045, 0.063] | <0.001 |
| Time | 0.019 [-0.085, 0.124] | 0.716 | 0.032 [-0.071, 0.135] | 0.541 |
| Baseline DBP | 0.016 [0.005, 0.026] | 0.003 | 0.009 [0.000, 0.017] | 0.044 |
| DBP change | 0.009 [0.004, 0.014] | <0.001 | 0.004 [0.000, 0.008] | 0.076 |
| Baseline WHR | 0.671 [-0.867, 2.210] | 0.392 | 0.945 [-0.307, 2.197] | 0.139 |
| WHR change | 0.132 [-0.685, 0.949] | 0.751 | -0.472 [-1.424, 0.481] | 0.331 |
| DBP x Time | 0.000 [-0.001, 0.001] | 0.653 | 0.000 [-0.001, 0.000] | 0.234 |
| WHR x Time | 0.013 [-0.091, 0.116] | 0.808 | 0.046 [-0.042, 0.134] | 0.304 |

**Table 11:** Gender-stratified results for Model M2 on executive function

|  | Females: Estimate  [95 % CI] | Females: p-value | Males: Estimate  [95 % CI] | Males: p-value |
| --- | --- | --- | --- | --- |
| Age at baseline | -0.019 [-0.032, -0.007] | 0.003 | -0.015 [-0.027, -0.003] | 0.016 |
| Time | -0.037 [-0.058, -0.015] | <0.001 | -0.055 [-0.075, -0.036] | <0.001 |
| Baseline WMH volume | 0.096 [-0.037, 0.229] | 0.155 | -0.127 [-0.273, 0.019] | 0.087 |
| Change in WMH volume | -0.208 [-0.517, 0.100] | 0.185 | -0.111 [-0.375, 0.154] | 0.413 |

**Table 12:** Gender-stratified results for Model M3 on global cognitive function

|  | Females: Estimate  [95 % CI] | Females: p-value | Males: Estimate  [95 % CI] | Males: p-value |
| --- | --- | --- | --- | --- |
| Age at baseline | -0.040 [-0.053, -0.028] | <0.001 | -0.048 [-0.059, -0.037] | <0.001 |
| Time | -0.028 [-0.046, -0.010] | 0.003 | -0.050 [-0.067, -0.034] | <0.001 |
| WMH volume baseline | 0.022 [-0.104, 0.149] | 0.728 | -0.113 [-0.244, 0.017] | 0.089 |
| Change in WMH volume | -0.371 [-0.636, -0.107] | 0.006 | -0.284 [-0.510, -0.058] | 0.014 |

**Table 13:** Results of an exploratory model testing the association of baseline and change in SBP with WMH progression

|  | Estimate [95 % CI] | p-value |
| --- | --- | --- |
| Age at baseline | 0.0504 [0.0438, 0.0571] | <1e-04 |
| Time between baseline and followup | -0.0331 [-0.0870, 0.0208] | 0.2290 |
| Systolic BP at baseline | 0.0051 [0.0013, 0.0089] | 0.0082 |
| Change in Systolic BP | 0.0050 [0.0033, 0.0067] | <1e-04 |
| Waist-to-hip ratio at baseline | 0.9273 [-0.0327, 1.8872] | 0.0583 |
| Change in WHR | -0.1219 [-0.7154, 0.4717] | 0.6871 |
| Interaction of time and SBP at baseline | 0.0005 [0.0002, 0.0007] | 0.0017 |
| Interaction of time and WHR at baseline | 0.0148 [-0.0318, 0.0613] | 0.5338 |

**Table 14:** Associations of DBP and WHR with progression of spatial WMH components

|  | C1: Estimate  [95 % CI] | C1: p-value | C2: Estimate  [95 % CI] | C2: p-value | C3: Estimate  [95 % CI] | C3: p-value | C4: Estimate  [95 % CI] | C4: p-value |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Age at baseline | 0.061 [0.053, 0.069] | <0.001 | 0.053 [0.044, 0.062] | <0.001 | 0.064 [0.055, 0.072] | <0.001 | 0.035 [0.025, 0.044] | <0.001 |
| Time | 0.027 [-0.008, 0.062] | 0.123 | 0.005 [-0.021, 0.030] | 0.729 | 0.057 [0.018, 0.097] | 0.005 | -0.011 [-0.034, 0.011] | 0.332 |
| Baseline DBP | 0.002 [-0.006, 0.010] | 0.611 | 0.010 [0.001, 0.018] | 0.024 | 0.009 [0.001, 0.017] | 0.027 | 0.006 [-0.003, 0.015] | 0.174 |
| DBP change | 0.001 [-0.001, 0.003] | 0.290 | 0.001 [0.000, 0.003] | 0.117 | 0.004 [0.002, 0.007] | <0.001 | 0.001 [0.000, 0.002] | 0.133 |
| Baseline WHR | 0.415 [-0.487, 1.317] | 0.367 | -0.478 [-1.457, 0.501] | 0.338 | -0.085 [-1.014, 0.843] | 0.857 | 0.280 [-0.734, 1.294] | 0.588 |
| WHR change | -0.220 [-0.598, 0.158] | 0.254 | 0.010 [-0.264, 0.284] | 0.945 | -0.095 [-0.518, 0.329] | 0.661 | 0.113 [-0.132, 0.357] | 0.366 |
| DBP x Time | 0.000 [0.000, 0.000] | 0.971 | 0.000 [0.000, 0.000] | 0.531 | 0.000 [0.000, 0.000] | 0.597 | 0.000 [0.000, 0.000] | 0.348 |
| WHR x Time | -0.018 [-0.047, 0.011] | 0.213 | -0.001 [-0.022, 0.020] | 0.919 | -0.020 [-0.053, 0.012] | 0.224 | 0.007 [-0.012, 0.026] | 0.449 |


**Table 15:** Associations of WMH spatial component progression with global cognitive function

|  | C1: Estimate  [95 % CI] | C1: p-value | C2: Estimate  [95 % CI] | C2: p-value | C3: Estimate  [95 % CI] | C3: p-value | C4: Estimate  [95 % CI] | C4: p-value |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Age at baseline | -0.049 [-0.058, -0.041] | <0.001 | -0.051 [-0.058, -0.043] | <0.001 | -0.049 [-0.057, -0.041] | <0.001 | -0.052 [-0.059, -0.045] | <0.001 |
| Time | -0.054 [-0.064, -0.044] | <0.001 | -0.054 [-0.064, -0.045] | <0.001 | -0.053 [-0.063, -0.043] | <0.001 | -0.054 [-0.064, -0.045] | <0.001 |
| Baseline component score | -0.036 [-0.109, 0.038] | 0.338 | 0.001 [-0.068, 0.069] | 0.985 | -0.030 [-0.101, 0.041] | 0.412 | 0.024 [-0.042, 0.090] | 0.483 |
| Change in component score | -0.048 [-0.119, 0.023] | 0.186 | -0.058 [-0.124, 0.008] | 0.086 | -0.074 [-0.143, -0.006] | 0.034 | -0.010 [-0.075, 0.055] | 0.765 |


**Figures**

****

**Figure 1:** Flowchart of the study

****


**Figure 2:** Results from M1 on the association of DBP and WHR and WMH progression model. Shown are scatter plots for associations of baseline and change in CVR factors with WMH volume. \*\*\* indicates p<0.001. The pizza chart illustrates the Bayes factor in favour of the alternative hypothesis.

****


**Figure 3:** Results from M2 associating WMH progression and executive function. Shown are scatter plots for associations of baseline and change in CVR factors with WMH volume. \*\*\* indicates p<0.001. The pizza chart illustrates the Bayes factor in favour of the alternative hypothesis.

****


**Figure 4:** Results from M3 associating WMH progression and global cognitive function. Shown are scatter plots for associations of baseline and change in CVR factors with WMH volume. \*\*\* indicates p<0.001.The pizza chart illustrates the Bayes factor in favour of the alternative hypothesis.





**Figure 5:** M1: Original estimate (black) with minimum and maximum estimate derived from random effect stability analysis (black line), estimate and 95% CI from robust LMM (dark red triangle and line) and estimates and 95% CI without 7 influential cases (colours indicate imputation).




**Figure 6:** M2: Original estimate (black) with minimum and maximum estimate derived from random effect stability analysis (black line), estimate and 95% CI from robust LMM (dark red triangle and line) and estimates and 95% CI without 27 influential cases (colours indicate imputation).

**Figure 7:** M3: Original estimate (black) with minimum and maximum estimate derived from random effect stability analysis (black line), estimate and 95% CI from robust LMM (dark red triangle and line) and estimates and 95% CI without 20 influential cases (colours indicate imputation).

**F****igure 8:** Example of Bullseye Segmentation. From left to right: Equidistant shells between ventricles and cortex, Segmentation of four brain lobes per hemisphere and basal ganglia region, combined Bullseye segmentation with 36 regions, probabilistic map of WMH.

**Figure 9:** Average WMH volume increase between baseline and follow-up in Bullseye WM regions

**Figure 10:** WMH spatial pattern derived from baseline WMH distribution. Labels indicate component number and variance explained. Distance from center represents four equidistant layers between ventricles and cortex, and angular orientation represents cerebral lobes and hemisphere. Colors indicate contribution of this region to the pattern.

1. the term “white matter lesions” (WML) was replaced by white matter hyperintensities (WMH) throughout the manuscript according to the Duering et al. ([2023](#ref-duering23)) [↑](#footnote-ref-1)